Regulation of glioblastoma cell proliferation in dependence of cell density and growth factors in vitro by Liu, Yun
Aus der Klinik für Strahlentherapie und Radioonkologie 
der Medizinischen Fakultät Mannheim 
(Direktor: Prof. Dr. med. Frederik Wenz) 
Regulation of glioblastoma cell proliferation in dependence of cell density 
and growth factors in vitro 
Inauguraldissertation 
zur Erlangung des Doctor scientiarum humanarum (Dr. sc. hum.) 
der 










Dekan: Prof. Dr. med. Sergij Goerdt 
Referent: Prof. Dr. med. Frederik Wenz 
CONTENTS 
 Pages 
LIST OF ABRREVIATIONS ..................................................................... 1 
 INTRODUCTION ................................................................................. 3 1
1.1 Glioblastoma ................................................................................................. 3 
1.2 GBM cell biology ............................................................................................ 4 
1.2.1 Loss of cell cycle control ...................................................................... 4 
1.2.2 Resistance to apoptosis ....................................................................... 6 
1.2.3 Invasion and migration ......................................................................... 6 
1.3 Growth factors and kinases in GBM .............................................................. 7 
1.3.1 Growth factor ....................................................................................... 7 
1.3.2 Receptor tyrosine kinase ..................................................................... 8 
1.4 Major oncogenic pathways in GBM ............................................................. 10 
1.4.1 PI3K/AKT signaling pathway ............................................................. 11 
1.4.2 MAPK signaling pathway ................................................................... 12 
1.5 Influence of cell density on GBM proliferation in vitro .................................. 15 
1.5.1 Focal adhesion kinase ....................................................................... 15 
1.5.2 Contact inhibition ............................................................................... 16 
1.6 Aim of the study ........................................................................................... 18 
 MATERIALS AND METHODS ........................................................... 19 2
2.1 Materials ...................................................................................................... 19 
2.1.1 Chemicals and reagents .................................................................... 19 
2.1.2 Growth factors ................................................................................... 21 
2.1.3 Inhibitors ............................................................................................ 21 
2.1.4 Buffer preparation .............................................................................. 21 
2.1.5 Antibodies .......................................................................................... 23 
2.1.6 Cell culture materials ......................................................................... 24 
2.1.7 Apparatus and software ..................................................................... 24 
2.2 Methods ....................................................................................................... 25 
2.2.1 Cell culture ......................................................................................... 25 
2.2.2 Proliferation assay ............................................................................. 26 
2.2.3 Detachment assay ............................................................................. 28 
2.2.4 Western blotting ................................................................................. 29 
2.2.5 Caspase 3 activity.............................................................................. 30 
2.2.6 Colony forming assay ........................................................................ 31 
2.2.7 Flow cytometry................................................................................... 31 
2.2.8 Immunoflurescence ........................................................................... 32 
2.2.9 Statistics ............................................................................................ 33 
 RESULTS .......................................................................................... 34 3
3.1 Effect of culture conditions on cell proliferation ........................................... 34 
3.1.1 GBM cells undergo apoptosis under certain conditions ..................... 34 
3.1.2 EH cells have G2 arrest and downregulation of cell cycle proteins.... 38 
3.1.3 Effect of FAK on EH cell apoptosis .................................................... 41 
3.1.4 Effect of upregulation of p27 on EH cell apoptosis ............................ 43 
3.2 The balance between ERK1/2 and JNK activation in parent cultures .......... 45 
3.2.1 ERK1/2 activation in parent cultures .................................................. 45 
3.2.2 The regulation of ERK1/2 and JNK activation .................................... 47 
3.3 Radiation response of U251 cells from different parent cultures ................. 52 
3.3.1 Clonogenic survival of U251 cells from different parent cultures ....... 52 
3.3.2 Induction and decay of DSBs after irradiation .................................... 54 
3.4 Effect of different growth factors on proliferation of GBM cells in vitro......... 56 
3.5 Contact inhibition retained in glioblastoma cells in vitro ............................... 60 
 DISCUSSION .................................................................................... 67 4
4.1 Role of FAK in regulating apoptosis ............................................................ 67 
4.2 Role of ERK1/2 and JNK activation in GBM ................................................ 68 
4.2.1 Regulation of ERK1/2 and JNK ......................................................... 68 
4.2.2 Effect of ERK1/2 on radiation response ............................................. 71 
4.3 Role of cyclin-dependent kinase inhibitor p27 ............................................. 73 
4.4 Role of exogenous growth factors ............................................................... 75 
 SUMMARY ........................................................................................ 77 5
 REFERENCE .................................................................................... 79 6
 LIST OF FIGURES AND TABLES ..................................................... 91 7
7.1 List of figures ............................................................................................... 91 
7.2 List of tables ................................................................................................ 93 
 CURRICULUM VITAE ....................................................................... 94 8
 ACKNOWLEDGEMENT .................................................................... 95 9
 
LIST OF ABRREVIATIONS 
1 
LIST OF ABRREVIATIONS 
°C grad Celsius 
µ Micro (10-6) 
APS Ammonium persulfate 
BSA Bovine serum albumin 
CDK Cyclin-dependent kinase 
CDKI Cyclin-dependent kinase inhibitor 
DAPI 4',6-diamidino-2-phenylindole 
DMEM Dulbecco´s modified eagle medium 
DMSO Dimethyl sulfoxide 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
ERK1/2 Extracellular signal-regulated kinase1/2 
FAK Focal adhesion kinase 
FBS Fetal bovine serum 
FGF-2 Fibroblast growth factor-2 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GBM Glioblastoma multiforme 
GSC Glioma stem cell 
HCl Hydrogen chloride 
HRP Horseradish peroxidase 
IGF-1 Insulin-like growth factor-1 
IGF-1R Insulin-like growth factor-1 receptor 
JNK c-Jun N-terminal kinase 
kg kilo gram 
m Milli (10-3) 
min Minute 
M molar (mol/l) 
MAPK Mitogen-activated protein kinase 
MGMT O(6)-methyl-guanine DNA methyl transferase 
LIST OF ABRREVIATIONS 
2 
mTOR Mammalian target of rapamycin 
NF-1 Neurofibromatosis type I 
NSC Neural stem cell 
PAGE Polyacrylamide-Gel-electrophoresis 
PBS Phosphate buffered saline 
PFA Paraformaldehyde 
PDL Poly-D-lysine hydrobromide 
PI Propidium Iodide 
PI3K Phosphatidylinositol-3-kinase 
PIP3 Phosphatidylinositol 3, 4, 5-triphosphate 
PLO Poly-L-ornithin hydrobromide 
PTEN Phosphatase and tensin homolog deleted on chromosome 10 
rmp Revolutions per minute 
RTK Receptor tyrosine kinase 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
SE Standard error  
TBS Tris buffered saline 
TBS-T Tris buffered saline with Tween20 
TEMED N,N,N´,N´-Tetramethylethylenediamine 
TGF-β Transforming growth factor β 
Tris Tris(hydroxymethyl)-aminoethane 






According to the World Health Organization (WHO) grading scale, gliomas are 
categorized based on histological characteristics as low-grade astrocytoma (WHO 
grade I and II), anaplastic astrocytoma (WHO grade III) and glioblastoma multiforme 
(WHO grade IV) [1]. Glioblastoma multiforme (GBM) is the most common primary 
malignant tumor of the central nerve system, with an average incidence of 3-4 in 
100,000 people newly diagnosed per year in the United States [2]. GBM can occur at 
any age, but is more frequently diagnosed in elder population with the median age of 
64 years [3].   
The current standard treatment for newly diagnosed GBM comprises of maximal safe 
surgery, followed by radiotherapy with temozolomide (TMZ) [4]. Despite the 
improvements in treatment modalities, the clinical outcome in GBM still remains 
disappointing, and the median survival time hardly reaches 15 months [5]. Several 
variables have been regarded as prognostic factors, including age, tumor size and 
location, and extent of surgery [6, 7]. Surgical resection plays a critical part in the 
management of GBM. The importance of aggressive tumor removal has been 
emphasized due to the association between greater extents of surgical resection and 
better outcome for patients with GBM [8]. However, GBM cells show aggressive 
behavior with high invasion and diffuse infiltration into surrounding brain parenchyma, 
making it impossible to completely remove tumor cells [9]. The goal of radiotherapy 
coupled with chemotherapeutic agents is to eliminate residual tumor cells. The 
standard of care is the concomitant use of TMZ and radiotherapy up to 60Gy over 30 
days followed by 6 cycles of adjuvant TMZ treatment [5]. TMZ is an alkylating agent 
that induces DNA damage and thus causes cell death [10]. However, the effect of 
such alkylating agents can be impaired by O6-methylguanine DNA methyltransferase 
(MGMT) which is a DNA repair enzyme. MGMT expression is suppressed by 
methylation of the promoter region of the MGMT gene [11]. Therefore, methylation of 
the MGMT promoter has been shown as a strong predictive factor of patients 
undergoing chemotherapy with TMZ [12, 13].  
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Radiotherapy is a powerful tool in cancer treatment and has yielded significant 
survival benefit for patients with GBM [14]. The standard protocol of postoperative 
radiotherapy is to deliver a total dose of 60Gy in 2Gy per fraction using external-
beam radiation. However, the effectiveness of radiotherapy is limited by resistance to 
tumor cell death after exposure to ionizing irradiation, which is referred as radio-
resistance. GBM is one of the most radio-resistant malignancies because 90% of 
GBM patients experience local recurrence despite aggressive treatment [15]. It has 
been recognized that radio-resistance is mediated by both intrinsic and extrinsic 
factors. These factors include DNA damage repair, accelerated tumor repopulation 
after fractionated RT, tumor heterogeneity, as well as radiation-induced 
microenvironment changes which provide suitable conditions for tumor survival [16, 
17]. Notably, Glioma stem cells (GSC) contribute to GBM radio- and chemo-
resistance due to their unique characteristics of quiescent cell cycle, enhanced 
expression of drug-resistant protein, DNA repair capacity as well as resistance to 
apoptosis [18, 19]. To a better integrative overview, it is important to gain insights into 
the biology and molecular pathogenesis of GBM.  
1.2 GBM cell biology  
GBM arises from a number of genetic alterations, oncogene activation, and tumor 
suppressor gene inactivation [20]. The initiation and progression of GBM is complex, 
and is driven by multiple intracellular events, which promotes cell proliferation, 
survival, invasion and angiogenesis. The hallmarks of GBM include loss of cell cycle 
control, resistance to apoptosis, invasion and migration, which leads to aggressive 
behavior of this dismal tumor and even resistance to therapies [21, 22]. 
Understanding the distinct molecular biology of GBM will enable further effects to 
specifically interfere with its inherent alterations to achieve a more effective therapy.  
1.2.1 Loss of cell cycle control 
The cell cycle is the process by which a eukaryotic cell is duplicated and segregated 
into daughter cells. It is comprised of four phases: G1 (gap1) phase when cells 
synthesize mRNA and protein for DNA synthesis; S (synthetic) phase when DNA 
replicates; G2 (gap2) phase when cells synthesize protein; M (mitotic) phase when 
duplicated chromosomes are divided into two daughter cells [23]. In normal cells, cell 
cycle progression is under strict control by the coordinated activities of cyclin/cyclin-
dependent kinases (CDK) complexes, which act as master regulators to govern cell 
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cycle progression by phosphorylating downstream substrates [23, 24]. It is well 
known that cyclin D-CDK4/6, cyclin E-CDK2, cyclin B–CDK1 and cyclin A–CDK1/2 
are critical for cell cycle progression through G1/S transition, S phase and G2/M 
transition, respectively [25]. On the other hand, cyclin-dependent kinase inhibitors 
(CDKIs) are able to control cell cycle progression by binding to CDKs [26]. For 
instance, the cell cycle inhibitor p16 belongs to the INK4 family of CDKIs and 
negatively regulates cell cycle transition by binding to CDK4. The cell cycle inhibitor 
p27 and p21 are members of the Cip/Kip family and exhibit broad CDK inhibitory 
activity, including interacting with cyclin D–CDK4/6 to negatively control the G1/S 
transition [27, 28]. Several signaling pathways have been involved in the regulation of 
cell cycle progression, including the retinoblastoma pathway (RB) and p53 pathways. 
In quiescent cells, RB associates with the transcription factor E2F to prevent cell 
progression into S phase. Upon stimulation, activated cyclin D-CDK4/6 
phosphorylates and inactivates RB, enabling the release of E2F that activates genes 
required for the G1/S transition [27]. The p53 pathway is well known to be involved in 
cell cycle arrest, apoptosis, senescence and DNA damage repair [29]. In response to 
DNA damage, p53 is activated and acts as a transcription factor. One of the well 
characterized effectors is p21 that functions as a critical regulator of cell cycle 
progression in G1 phase [30]. P53 is stabilized by binding to p14 and degraded by 
murine double minute 2 (MDM2). Loss of cell cycle control due to genetic alterations 
in these cell cycle regulators has been proposed to be associated with tumorigenesis 
of several tumors, including GBM [31, 32].  
Dysregulation of RB signaling has been reported in about 80% of GBM and is 
implicated in the progression of astrocytoma [33]. Alterations of this pathway include 
genetic loss of RB, CDK4/6 amplification as well as deletion of CDKN2A coding for 
p16, causing uncontrolled cell cycle [34]. P53 mutation has been documented in 
primary GBM with a low frequency of 28-35%, and loss of p53 is frequently observed 
in the pathological progression of secondary GBM [35, 36]. Alterations of p53 
pathway are associated with inactivation of cell cycle inhibitor p14 and amplification 
of MDM2 [33]. Dysregulated p53 pathways impair cell cycle progression by affecting 
both G1/S and G2/M transition [37]. It has also been reported that p53 is associated 
with G2/M arrest induced by TMZ, and altered p53 expression affects the response of 
GBM cells to TMZ [38, 39]. 
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1.2.2 Resistance to apoptosis 
Apoptosis is a highly regulated process whereby cells undergo programmed cell 
death. The process can be achieved either through the intrinsic pathway or the 
extrinsic pathway [40]. The intrinsic pathway is initiated by signals inside the cell, 
such as DNA damage and growth factor deprivation, and is regulated by pro- and 
anti-apoptotic proteins of the B-cell lymphoma 2 (BCL-2) family. The extrinsic 
pathway is triggered from outside the cell by binding of death inducing ligands to cell 
surface receptors [41]. 
Evasion of apoptosis is a hallmark of tumors, including GBM [42]. GBM cells exhibit 
intrinsic deregulation in apoptosis signaling pathways and develop complex 
mechanisms to evade its accompanying cell death, thereby promoting cell survival 
[43]. For instance, the anti-apoptotic BCL-2 family members BCL-2 and BCL-XL have 
been reported to be up-regulated in initial and recurrent GBM, while the pro-apoptotic 
BCL-2 protein BAX was down-regulated. This indicated that the dysregulated BCL-2 
proteins contributed to enhanced anti-apoptotic capacity of GBM cells [44]. On the 
other hand, as a notable regulator in apoptotic response, p53 is found to regulate the 
expression of the pro-apoptotic proteins [45]. 87% of GBM harbor impaired p53 
pathways, which leads to deregulation of apoptosis signaling and increased 
resistance to treatment-induced apoptosis [46].  
1.2.3 Invasion and migration 
The rapid progression of GBM is related to their ability to infiltrate into surrounding 
brain parenchyma, by way of invasion and migration. Invasive GBM cells escape 
complete surgical removal and hide from lethal radiation exposure, which is 
responsible for disease progression or even recurrence [47, 48]. Tumor cell invasion 
requires several steps, including detachment from the primary tumor mass, adhesion 
to extracellular matrix (ECM), degradation and remodeling of ECM, and cell motility 
through brain parenchyma [49]. Infiltration of GBM cells into brain tissue is 
determined by the interactions between tumor cells and extracellular 
microenvironment [50]. A multitude of molecules are involved, including adhesion 
molecules, cytoskeletal proteins, ECM components and proteases [48]. Integrins are 
the most common adhesion molecules that allow cell to adhere to ECM proteins such 
as laminin, collagens, matrigel and fibronectin [51]. In GBM, the binding of ECM to 
cell integrins mediates various intracellular signals interaction with growth factors and 
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receptors, leading to enhanced GBM cell adhesion, proliferation and migration [52]. 
Focal adhesion kinase (FAK) has been proposed as a key component of integrin-
mediated signal transduction pathways, which is overexpressed in invasive GBM 
cells [53]. In addition to cell adhesion, GBM expresses elevated levels of matrix 
metalloproteases (MMPs), by which tumor cells are able to degrade and remodel 
ECM proteins, favoring cell invasion [54]. 
1.3 Growth factors and kinases in GBM  
GBM produces various kinds of growth factors and expresses the corresponding 
membrane receptor kinases, which overall confers growth advantage to tumor cells. 
Upon the binding of diffusible growth factors to transmembrane receptors, mitogenic 
signaling pathways are activated and subsequently transduce intracellular signals 
required for cell growth, proliferation, and survival [55]. Tumor cells acquire the ability 
to decrease their dependence on exogenous growth factors by altering receptor 
kinases and downstream signaling pathways [56].   
1.3.1 Growth factor 
Growth factors are major regulators in tumor progression and GBM is enriched in a 
variety of growth factors, including IGF-1, FGF-2, EGF, PDGF, VEGF and others 
[57]. Three key growth factors in GBM are described below. 
The epidermal growth factor (EGF): EGF and its epidermal growth factor receptor 
(EGFR) are important in mediating the proliferative and transforming responses via 
autocrine or paracrine mechanisms [58]. The significant roles of EGF/EGFR have 
been well established in GBM [59]. As a potent mitogen, the primary function of EGF 
is to promote the growth of GBM cells by stimulating DNA synthesis and cell division 
via EGF/EGFR signaling pathway [60]. It has been shown that EGF expression level 
was upregulated in the GBM tumor region, but reduced in the cerebrospinal fluid after 
surgical resection of the tumor, indicating a crucial role of EGF in the course of GBM 
progression [61]. In addition to its mitogenic effects, EGF has been reported to 
participate in the key processes of GBM cell invasion and angiogenesis [62-64]. 
Notably, EGF is essential for the maintenance of neural stem cells (NSC) as well as 
glioma stem cells (GSC), by promoting sphere formation and self-renewal capacity 
[65].   
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Fibroblast growth factor family (FGFs):  FGFs play crucial roles in a wide range of 
cellular processes, such as cell proliferation, differentiation, migration and 
angiogenesis [66]. Of all the members in this family, FGF-1 and FGF-2 have been 
implicated in GBM, and alterations of FGF/FGFR signaling pathways play a critical 
role in the malignant progression of this tumor type [67-69]. GBM is characterized by 
high vascularization and FGF-2 has been observed to contribute to the process of 
angiogenesis [62]. FGF-2 can enhance the proliferation of endothelial cells and 
cooperate with VEGF to promote angiogenesis [70]. Besides, it is demonstrated that 
FGF-2 derived from GBM cells was able to increase the blood brain barrier function 
of endothelial cells, leading to drug resistance in GBM [71]. Specifically for GSC, 
FGF-2 is considered as an essential supplement for self-renewal and maintenance 
GSC pool [72]. Moreover, FGF-2 is the most effective inducer of Nestin expression, a 
stem cell marker [73]. Withdraw of FGF-2 induces more differentiation of GSCs 
through asymmetric cell division [74].  However, the necessity of adding FGF-2 as a 
component in culture medium is still debatable. It has been reported that GSC can 
sustain their self-renewal independent of exogenous growth factors, mainly in an 
autocrine fashion due to secretion of FGF-2 by GSCs [75, 76]. Thus, to avoid 
undesired alterations in cell culture, it is critical to maintain GSC in vitro similar to 
their original tumor cells [77].  
Insulin-like growth factor (IGF) axis: The IGF signaling axis notably regulates cellular 
processes in normal cells as well as malignant cells [78]. The system is made up of 
ligands IGF-1 and IGF-2, transmembrane receptors IGF-1R and IGF-2R, as well as 
binding proteins IGFBP1-6. IGF-1 is a powerful mitogenic and anti-apoptotic factor 
involved in the control of cell proliferation, differentiation and apoptosis. The elevated 
levels of IGF-1 expression have been observed in GBM, suggesting the crucial role 
of IGF-1 in gliomagenesis [79]. Recently, Ho et al. showed that IGF-1 regulated GBM 
cell invasion by mediating cytokine secretions [80]. Since the important role of IGF-1 
is proposed in NCS proliferation [81], it might provide a growth benefit for the addition 
of IGF-1 as a supplement for GSC culture in vitro. 
1.3.2 Receptor tyrosine kinase 
Cellular receptors with tyrosine kinase function as key mediators of signal 
transduction. Once activated, receptor tyrosine kinases (RTK) initiate a stream of 
signals that regulate multiply of cell possesses. RTKs are transmembrane 
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glycoproteins that contain an amino-terminal extracellular ligand-binding domain, a 
single anchoring transmembrane domain, and a cytosolic carboxy-terminal domain 
with tyrosine kinase enzymatic activity [55]. Activation of RTK is initiated by a cognate 
ligand binding to extracellular domain of receptor, leading to receptor homo/hetero-
dimerization and other conformational changes. Juxtaposition of tyrosine kinase 
domain of both receptors stabilizes the active state of kinase and enables trans-
phosphorylation of tyrosine residues in kinase activation loop. The phosphorylated 
residues serve as docking sites for cytoplasmic proteins which contain Src homology 
or phosphor-tyrosine binding domains, such as PI3K, phospholipase C, growth factor 
receptor-binding protein, or the kinase Src [82]. 
Alterations of RTK through protein overexpression, genetic amplification or mutations 
are identified in most GBMs and considered to be an essential component of vital 
oncogenic pathways [22]. In the followings, two crucial RTKs are described in detail.  
Epidermal growth factor receptor (EGFR): EGFR, also referred to ERBB1and HER1, 
is a transmembrane protein belonging to ERBB family of RTKs. Other members with 
shared structure and function are ERBB2 (HER2), ERBB3 (HER3) and ERBB4 
(HER4) [83]. Dysregulated EGFR activation is considered the most common 
abnormality, occurring in about 57% of primary GBM patients [35]. EGFR activity is 
frequently upregulated due to amplification of the EGFR gene, overexpression of 
EGFR protein, or constitutively activation of oncogenic mutations [84]. The variant III 
EGFR deletion mutant (EGFRvIII) is the most common type of EGFR mutations 
expressed in about half of GBMs with EGFR amplification [85]. Due to the lack of 
binding domain, this truncated EGFR is constitutively activated and sustains a low 
level of autophosphorylation with decreased internalization and reduced degradation. 
This weak but continuous signal mediated by overexpression of EGFRvIII contributes 
to enhanced dysregulation of downstream pathways involved in amplified oncogenic 
effects,  including increased proliferation, angiogenesis, invasion, tumorigenicity  and 
resistant to therapy [85, 86]. 
EGFR dysregulation is associated with poor prognosis and decreased survival time in 
GBM patients [87]. However, a conflicting result was found by Quan et al. who 
showed no association of EGFR amplification with survival in patients with GBM [88]. 
Nevertheless, as a hallmark of high-grade GBM, alterations of EGFR are rare in low-
grade gliomas, indicating these alterations play a crucial role in the late event of 
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gliomagenesis and aggressive behavior [59]. Half of EGFR can translocate to the 
nucleus and interact with gene transcriptions that modulate radio- and chemo-
resistance [89]. In spite of high levels of EGFR expression, cells with amplified EGFR 
are prone to lose amplification in vitro [90]. In the commonly used glioblastoma cell 
line U251, Wang et al. found activation of EGFR was low under standard culture, 
implying EGFR activation may be not required for the transmission of mitogenic 
stimuli in U251cells [91].  
Insulin-like growth factor-1 receptor (IGF-1R): Activation of IGF system is mediated 
by ligand-receptor binding and further modulated by IGFBP, leading to signal 
transduction via PI3K/AKT pathway or MAPK pathway [92].  The aberrant signaling 
pathways mediated by overexpression of IGF-1R contribute to the growth, migration, 
angiogenesis and survival of malignant cells, including tumorigenesis of GBM [93]. 
Currently, IGF-1R expression has been considered as an independent prognostic 
factor associated with poor survival of patients with GBM. In addition, overexpression 
of IGF-1R was associated with resistance to TMZ in GBM patients [94]. With regard 
to radio-resistance, Osuka et al. showed that upregulation of IGF-1R induced by 
fractionated radiation had a radio-protective effect on GSCs via PI3K/AKT signaling 
pathway [95]. Besides, it has been reported that blockage of IGF-1R inhibited GBM 
growth mediated either by a direct effect on tumor cell proliferation or an effect on 
tumor vascularization [96]. Interestingly, IGF-1R was responsible for serum-induced 
activation of ERK1/2 in vitro, highlighting the motigenic effect of IGF-1R signaling 
[91]. 
1.4 Major oncogenic pathways in GBM  
Multiple cellular processes regulate cell proliferation and survival, with several 
signaling pathways playing pivotal roles in these contexts. The molecular 
pathogenesis of GBM is a complex interconnected network involved in the alterations 
of key signaling pathways, which drives tumor cells with features of uncontrolled 
proliferation and defective apoptosis [22]. In addition to alterations in tumor 
suppressive pathways such as RB and p53 pathways, activation of oncogenic 
pathways contributes to growth, survival and invasion of GBM [97]. The major 
oncogenic pathways involving RTKs in GBM are PI3K-AKT-mTOR and MAPK/RAS-
RAF-ERK1/2 signaling pathways. 
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1.4.1 PI3K/AKT signaling pathway 
PI3K/AKT/mTOR signaling pathway is one of the crucial signaling pathways 
regulating cell cycle, cell survival and growth (Figure 1) [98]. Its signal transduction is 
initiated by membrane-bound RTK phosphorylation followed by activation of 
phosphoinositide 3-kinases (PI3K) [99]. PI3K then phosphorylates 
phosphatidylinositol 4, 5-bisphosphate (PIP2) to generate phosphatidylinositol 3, 4, 
5-triphosphate (PIP3). This process can be reversed by phosphatase and tension 
homolog deleted on chromosome ten (PTEN) which dephosphorylates PIP3 [100]. 
The main function of PIP3 is to serve as docking sites for intracellular signaling 
proteins containing pleckstrin-homology domains and recruit serine/threonine kinase 
3′-phosphoinositide-dependent kinase1 (PDK1) and protein kinase B (PKB) known as 
AKT to plasma membrane. Once translocated to the membrane, AKT is 
phosphorylated by PDK1 via its activation loop at threonine 308 as well as by DNA-
dependent protein kinase or mammalian target of rapamycin (mTOR) at Serine 473 
[101]. AKT activation mediates diverse cellular functions by further activating multiple 
downstream substrates. Specifically, AKT promotes cell survival by targeting 
apoptosis-related genes such as Bad, forkhead transcription factors, apoptosis 
signal-regulating kinase 1, glycogen synthase kinase-3 and caspase 9 [102]. 
Besides, AKT has been shown to regulate the cell cycle through cyclin D1, cyclin E 
and p21 [103]. mTOR is also a crucial target of AKT by phosphorylation of tuberous 
sclerosis complex-2 (TSC2) and disruption with TSC1-TSC2 complex. Activation of 
mTOR results in protein synthesis by phosphorylation of p70 S6 kinase and 




Figure 1. Schematic illustration of PI3K/AKT/mTOR pathway [98].  
Dysregulation of PI3K/AKT signaling pathways is frequently induced by loss-of-
function mutations in negative regulators, or gain-of-function alterations in RTK, and 
plays a significant role in driving gliomagenesis [104]. 
Constitutive activation of AKT has been observed in 80% GBM, which contributes to 
altered PI3K/AKT pathway in nearly 90% of GBM [35]. However, mutation of AKT is 
rarely detected in human GBM. AKT activity is elevated by loss of PTEN in GBM and 
also mutation in PI3K regulatory subunit [105, 106]. As a negative regulator of AKT, 
loss of PTEN leads to constitutive activation of PI3K/AKT pathway, which is also 
associated with tumorigenesis [107]. About 50% of GBM patients harbor tumors with 
genetic loss, mutation or epigenetic inactivation of PTEN [104, 108]. Also in 
commonly used glioblastoma cell lines including U251, AKT is constitutively activated 
due to the absence of PTEN [91, 109]. Elevated expression of phosphorylated AKT is 
associated with poor prognosis in patients with GBM [110]. It has been documented 
that irradiation can induce AKT activation which modulates radio-resistance in GBM  
[111]. Therefore, targeting AKT is a potential option for increase of radiation 
sensitivity in GBM, including primary glioma stem cells [112, 113].   
1.4.2 MAPK signaling pathway 
Mitogen-activated protein kinase (MAPK) is the main mitogenic signaling initiated by 
RTKs in both normal cells and tumor cells [114]. The pathway is activated by ligands 
binding to RTKs, leading to receptor dimerization and trans-phosphorylation. 
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Phosphorylated residues serve as binding sites containing Src homology 2 (SH2) or 
phosphotyrosine binding (PTB) domains like SHC. SHC then recruits growth factor 
receptor-bound protein 2 (Grb2) and guanine exchange factor son of sevenless 
(SOS) as adaptor proteins, allowing release of GDP and binding of GTP on RAS. 
Activated RAS can then lead to translocation of serine/threonine kinase RAF to 
plasma membrane where RAF is phosphorylated and activated. RAF further 
activates MEK, which phosphorylates ERK. Upon activation, ERK translocate to the 
nucleus to interact with transcription factors involved in diverse cellular functions such 
as cell proliferation, differentiation, cell cycle progression, protein synthesis and 
migration [115, 116]. Neurofibromin is the product of tumor suppressor gene 
Neurofibromatosis type I (NF-1) and functions as a negative regulator of RAS [117].  
Regulated MAPK signaling is important for normal cell growth and proliferation, 
whereas a constitutive activation of this pathway plays a critical role in tumor 
formation and progression [118]. MAPK cascades facilitate excessive proliferative 
phenotype – a key characteristic of GBM. Approximately 88% of GBM possess at 
least one alteration that contributes to aberrant activation of MAPK signaling 
pathways, including RTK overexpression, activating ligands via sustained autocrine 
or paracrine, B-RAF gene mutation or NF-1 gene deletion [35]. It is reported that 
enhanced p-MAPK was associated with increased radiation resistance in patients 
with GBM [119]. Moreover, activated MAPK expression is considered as a strong 
independent prognostic marker for a poor clinical outcome [120].  
MAPKs are a family of serine/threonine kinases and conventional MAPKs contain 
three members: extracellular signal-regulated kinase1/2 (ERK1/2), c-Jun N-terminal 
kinase (JNK) and p38 MAPK. ERK5 now is considered an additional MAPK. Despite 
sharing structural homology, different members are activated via different stimuli and 
initiate individual MAPK cascades (Figure 2) [118]. The critical roles of ERK1/2 and 




Figure 2. Schematic illustrations of MAPK pathways [118]. 
Extracellular signal-regulated kinase 1/2 (ERK1/2): ERK1/2 is the best characterized 
MAPK family. RAS/RAF/MEK/ERK1/2 cascade is the classical signal transduction 
required for cell survival and proliferation. Enhanced ERK1/2 activity has been found 
in tumor tissue of GBM patients, suggesting that ERK1/2 activation contributes to 
gliomagenesis [121]. Besides, the presence of constitutive ERK1/2 activation has 
been illustrated in glioma cell lines as well as primary culture of GBM [122]. In a 
recent study, ERK1/2 has been shown to be involved in the dispersal and growth of 
human primary GBM cells [123]. As a downstream effector of RTK, the relationship 
between ERK1/2 activation and RTK overexpression remains controversial in GBM. 
Lopez-Gines et al. demonstrated that 50% of GBM tissues with ERK1/2 expression 
had EGFR amplification [124]. However, Antonelli et al. showed that EGFR was not 
expressed in pediatric high-grade astrocytoma and was not related to ERK1/2 
activation [125]. A possible explanation may be the involvement of other RTKs in 
ERK1/2 activation. Wang et al. found ERK1/2 activation under normal cell culture 
with FBS was mediated via IGF-1R signaling but not EGFR in U251 cells [91]. It is 
also suggested that PDGFRA expression controlled growth of GBM cells via 
regulation of ERK1/2 activity [126].  
C-Jun N-terminal kinases (JNKs): JNKs also belong to MAPK family but are 
considered as stress-activated protein kinases, due to their activation predominantly 
by environmental and genotoxic stresses and to a lesser extent by growth factors 
[127]. JNKs have three isoforms: JNK1, JNK2 and JNK3 and activation of JNKs 
Introduction 
15 
requires phosphorylation of tyrosine and threonine residues in a reaction catalyzed 
by the dual-specificity kinase MKK4 and MKK7 [128]. JNKs pathway can sense and 
process stress signals and participate in a spectrum of cellular functions regarding 
inflammation, DNA damage response, transformation and apoptosis [129]. A well-
known substrate for JNKs is a transcription factor c-Jun leading to elevated activity of 
activator protein-1 [128]. JNKs have been identified to play context-dependent roles 
in both cell proliferation and apoptosis [130]. As an oncogene, JNK signaling pathway 
is critical for cell proliferation, survival and inflammation in cancers, including GBM 
[131]. It has been reported that constitutive activation of JNK contributes to enhanced 
transformation and resistance to apoptosis in GBM [132, 133]. Consistent with its role 
as a tumor suppressor, several studies have found significant activation of JNK in 
apoptosis mediated by several agents in GBM [134-136]. Furthermore, JNK 
activation is involved in radiation-induced apoptosis [137]. Therefore, further 
investigation is needed to find out more details regarding the role of ERK1/2 and JNK 
activation in GBM cell proliferation and survival. 
1.5 Influence of cell density on GBM proliferation in vitro 
In a previous study, Wang et al. have found that ERK1/2 activity was strongly 
influenced by manipulating growth conditions in U251 cells in vitro. Specifically, 
passage of exponentially growing cells followed by re-seeding at high density 
resulted in complete downregulation of ERK1/2 phosphorylation compared with re-
seeding at low cell density. By contrast, cells released from plateau phase showed 
upregulation of ERK1/2 activation irrespective of cell density upon re-seeding [91]. 
Taken together, these data indicate an important role of cell density-dependent 
regulation in ERK1/2 activity, which mediates mitogenic signaling in GBM. However, 
the impacts of the dysregulated ERK1/2 activation on GBM cell proliferation have not 
been elucidated yet. The detailed underlying mechanisms remain to be explored. To 
date, several studies have demonstrated that cell density induced biological effects 
on cell proliferation might be mediated via FAK signaling pathway and related to cell 
contact inhibition [138-140].  
1.5.1 Focal adhesion kinase 
FAK is a non-receptor tyrosine kinase and resides at the sites of integrin clustering. 
FAK can be activated by interactions with integrin as well as growth factor receptors, 
thus transmitting cell adhesion-dependent or growth factor-dependent signals to cell 
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interior [141]. Phosphorylation of FAK at Y397 results in its association with tyrosine 
kinase Src, which leads to phosphorylation of other tyrosine residues including 
tyrosine 925 and then full activation of FAK. Activated FAK recruits Grb2 adaptor 
protein, leading to activation of MAPK signaling pathway. FAK phosphorylation can 
also induce activation of PI3K/AKT signaling pathway [142]. Therefore, as a key 
mediator in cell signaling involving cell matrix interaction, FAK participates in multiple 
cell functions and promotes cell proliferation, migration and adhesion [143]. A handful 
of studies have shown that GBM cells express upregulated FAK activity both in vitro 
and in vivo. In human GBM tumor biopsy samples, the expression of FAK was 
elevated compared to normal brain [53, 144]. Overexpression of FAK enhances the 
activity of RAS and subsequently ERK1/2 signaling, which contributes to GBM 
proliferation and invasion [145-147].  
FAK signaling pathway may mediate ERK1/2 activity in response to the changes in 
cell density. First, the relationship between FAK and cell density has been 
documented. FAK phosphorylation is associated with cell density, and tyrosine 
phosphorylation of focal adhesion components is altered in a density-dependent 
manner [140, 148]. In human glioblastoma cells, cell density can modulate survival 
signaling via activation of FAK [149]. Second, as a potential downstream effector of 
FAK, ERK1/2 activation upon cell adhesion to ECM is dependent on FAK signaling 
[150, 151]. It has been proposed that FAK interacts with IGF-1R and these two 
signaling pathways converge [152]. Since Wang et al. showed that IGF-1R was 
responsible for ERK1/2 activation under serum-culture condition [91], it is possible 
that the crosstalk between these two pathways coordinately mediate ERK1/2 
activation. Therefore, the possible involvement of FAK signaling needs further 
investigation. 
1.5.2 Contact inhibition 
The proliferation of normal cells stops when they reach high densities and come in 
contact with each other even in the presence of extracellular nutrients. This process 
is termed contact inhibition or density-dependent inhibition of cell division [153]. 
Normal cells stop proliferation when they form monolayer in culture vessel. Unlike 
normal cells, lack of contact inhibition is a hallmark of tumor cells. They continue to 
proliferate when confluency and pile up upon each other [21]. Contact inhibition is 
mediated by elevated levels of CDKIs including p16 and p27, which can arrest cell 
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proliferation in G1 phase of the cell cycle by binding of cyclin-CDK complexes [154]. 
Tumor cells are refractory to contact inhibition due to the absence of p27 induction 
[155]. A number of signaling pathways have been implicated in the process of cell 
contact inhibition, including FAK, Hippo, p38/MAPK and Merlin/EGFR [140, 156-158]. 
Previously, Wang et al. observed that ERK1/2 downregulation was inversely related 
to upregulated p27 expression when exponential growth cells are re-seeded at high 
density, indicating a certain degree of contact inhibition is preserved in U251 cells. 
Contact inhibition is rarely described in aberrant tumor cells. Therefore, it would be of 


















1.6 Aim of the study 
Based on the previous findings that ERK1/2 activation was strongly influenced by 
culture conditions including cell density in U251 cells, the objective of the study was 
to investigate the impact of cell density as well as growth factors on glioblastoma cell 
proliferation and the underlying mechanisms. Specifically, the aims were to: 
I. study the effect of changes in cell culture conditions including cell density on 
proliferation of U251 cells 
II. study the effect of FAK on ERK1/2 activity induced by changes in culture 
conditions  
III. investigate ERK1/2 regulation in different culture conditions and study the 
effect of ERK1/2 activity on radiation response in U251 cells   
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 MATERIALS AND METHODS 2
2.1 Materials 
2.1.1 Chemicals and reagents 
Table 1. Chemicals and reagents 
Chemicals and reagents Product No. Company 
AC-DEVD-AFC (substrate) 13401 AAT Bioquest, Sunnyvale, 
USA 
Advanced DMEM/F-12 12634010 Life Technologies, Bleiswijk, 
Netherlands 
Albumin fraction V (BSA) 80764 Carl Roth, Karlsruhe, 
Germany 
Ammonium persulfate (APS) A3678 Sigma-Aldrich , Steinheim, 
Germany 
BIT 9500 serum substitute 09500 Stem cell, Vancouver, 
Canada 
Bradford Quick Start™ Bradford  5000205 Bio-Rad, Munich, 
Germany 
Bovine Serum Albumin Standard  
Quick Start™ 
5000206 Bio-Rad, Munich, 
Germany 




Carl Roth, Karlsruhe, 
Germany 
Collagenase IV 17104019 Life Technologies, Bleiswijk, 
Netherlands 
4',6-diamidino-2-phenylindole (DAPI) D21490 Life Technologies, Bleiswijk, 
Netherlands 




11320-074 Life Technologies, Bleiswijk, 
Netherlands 
Dimethyl sulfoxide (DMSO) 4720.1 Carl Roth, Karlsruhe, 
Germany 
DRAQ5 4084S Cell signaling Techonology, 
Frankfurt am Main, Germany 
EDTA 112K0765 Sigma-Aldrich, Steinheim, 
Germany 
Ethanol 100% 5054.2 Carl Roth, Karlsruhe, 
Germany 
Fetal bovine serum (FBS) S0115 Biochrom AG, Berlin, 
Germany 
Fibronectin 356008 BD Bioscience, Heidelberg, 
Germany 
Glutamine K0302 Biochrom AG, Berlin, 
Germany 
Glycine 3908.3 Carl Roth, Karlsruhe, 
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Germany 
Hydrochloric acid fuming 37% 
 
4625 Carl Roth, Karlsruhe, 
Germany 
2x Laemmli sample buffer 161-0737 Bio-Rad, Munich, 
Germany 
PageRuler™ Plus Prestained Protein 
Ladder 
26619 Life Technologies, Bleiswijk, 
Netherlands 
β-Mercaptoethanol 4227.1 Carl Roth, Karlsruhe, 
Germany 
Methanol 1627.6 Carl Roth, Karlsruhe, 
Germany 
Dulbecco’ Phosphate-Buffered Saline (PBS) L1825 Biochrom AG, Berlin, 
Germany 
Paraformaldehyde 37% P733.2 Carl Roth, Karlsruhe, 
Germany 
Penicillin/streptomycin 3029 Sigma-Aldrich, Steinheim, 
Germany 
Phosphatase Inhibitor Cocktail 2 P5726 Sigma-Aldrich, Steinheim, 
Germany 
Rotiphorese® Gel30 3029 Carl Roth, Karlsruhe, 
Germany 
RPMI 1640 Medium FG1215 Biochrom AG, Berlin, 
Germany 
Poly-D-lysine hydrobromide (PDL) P7280 Sigma-Aldrich, Steinheim, 
Germany 
Poly-L-ornithine hydrobromide (PLO) P3655 Sigma-Aldrich, Steinheim, 
Germany 
Sodium chloride (NaCl) 3957.2 Carl Roth, Karlsruhe, 
Germany 
Sodium dodecyl sulfate (SDS) L3771 Sigma-Aldrich, Steinheim, 
Germany 
TEMED T9281 Sigma-Aldrich, Steinheim, 
Germany 
Tris AE15.3 Carl Roth, Karlsruhe, 
Germany 
Triton® X-100 T8787 Sigma-Aldrich, Steinheim, 
Germany 
10% Tween® 20 1610781 Bio-Rad, Munich, 
Germany 
Trypsin L2133 Biochrom AG, Berlin, 
Germany 
Vectashield®mounting medium with DAPI H-1200 Vector Laboratories, 
Burlingame, USA 
Western Lightning PLUS 275-15021 Perkin Elmer, Shelton, 
USA 
Propidium Iodide (PI) P-1470 Sigma-Aldrich, Steinheim, 
Germany 
RNase A 19101 Qiagen, Hilden, Germany 
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2.1.2 Growth factors 
Table 2. Growth factors 
Growth factors Product No. Company 
Epidermal growth factor (EGF) GRF-10326 Immunological Sciences, 
Rome, Italy 
Basic fibroblast growth factor (FGF-2) GRF-15595 Immunological Sciences, 
Rome, Italy 
Insulin-like growth factor 1(IGF-1) 
 
50356 Biomol, Hamburg, 
Germany 
Transforming growth factor (TGF-β)  100-21C PeproTech Inc., Rocky Hill, 
USA 
2.1.3 Inhibitors 
Table 3. Inhibitors 
Inhibitor Product No. Company 
U0126  662005-5MG Merck KGaA, Darmstadt, 
Germany 
Erlotinib  CDS022564 Sigma-Aldrich, Steinheim, 
Germany 
AG1024  121767  Merck KGaA, Darmstadt, 
Germany 
2.1.4 Buffer preparation 
Table 4. Buffer 
Chemicals Ingredient 
APS (for WB) 1g APS 
add to 10ml ddH2O 
Assay buffer 50mM HEPES 
100 mM NaCl 
0.1% CHAPS 
10mM DTT 
100 µM EDTA 
10% Glycerol PH 7.4 
1% BSA 20mg BSA 
20ml 0.3% PBST 
Ladder (for WB) 950 µl Laemmli buffer 
50 µl β- Mercaptoethanol 
RIPA buffer, stock 50 mM Tris-HCl pH 7.2-7.6 
150 mM NaCl   
 2 mM EDTA    
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 0.1 % SDS  
0.5 % Sodium-Deoxycholate 
1% Nonidet P-40  
10% v/v Glycerol 
Lysis buffer ( ready to use for WB) 90  µl RIPA buffer 
1 µl Phosphatase Inhibitor 
15 µl Protease Inhibitor 




0.1 mM EDTA pH 7.4 
0.3% PBST PBS, 1× 
0.3 % Triton-X 
TBS, 10×  24.23g 0.2M Tris PH7.5,  
58.44g 1M NaCl,  
add to 1L ddH2O  
adjust pH value to 8.0 
TG, 10x  30.27 g 0.2M Tris,  
144g Glycine,  
add to 1L ddH2O 
adjust pH value to 8.3 
Transfer buffer 1× 
 
 




100ml TG 10×, 
200ml methanol, 
add to 1L ddH2O 
100ml TG 10x 
10ml 10%SDS 
add to 1L ddH2O 
100ml TBS 10x 
10ml 10%Tween 20 
add to 1L ddH2O 
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2.1.5 Antibodies 
Table 5. Antibodies 
Chemicals Product No. Company 
Phospho-p44/42 MAPK (ERK1/2)  
 
#9101 Cell signaling Technology, 
Frankfurt am Rhein, Germany 
p44/42 MAPK (ERK1/2)  #9102 Cell signaling Technology, 
Frankfurt am Rhein, Germany 
p27 Kip1 #2552 Cell signaling Technology, 
Frankfurt am Rhein, Germany 
Cyclin D1(92G2) #2978 Cell signaling Technology, 
Frankfurt am Rhein, Germany 
Cleave caspase 3 (Aps175) #9664S Cell signaling Technology, 
Frankfurt am Rhein, Germany 
Cleaved caspase 8 (Asp391) #9496 Cell signaling Technology, 
Frankfurt am Rhein, Germany 
Caspase 8 (1C12) #9746 Cell signaling Technology, 
Frankfurt am Rhein, Germany 
Phospho-PLK1 (Thr210) #9062 Cell signaling Technology, 
Frankfurt am Rhein, Germany 
Phospho-FAK Tyr397 sc-11765R Santa Cruz Biotechnology, 
Heidelberg, Germany 
Phospho-FAK Tyr925 Sc-11766 Santa Cruz Biotechnology, 
Heidelberg, Germany 
Phospho-SAPK/JNK (Thr183/Tyr185) #9251 Cell signaling Technology, 
Frankfurt am Rhein, Germany 
SAPK/JNK #9252 Cell signaling Technology, 
Frankfurt am Rhein, Germany 
CD133/2 (293C3) 130-090-851 Miltenyi Biotec, Teterow, 
Germany 
Ki67 ab15580 Abcam, Cambridge, U.K. 
Ki67 Alexa Fluor® 647 558615 BD Pharmingen™, Heidelberg, 
Germany 
SOX2 (E4) sc-365823 Santa Cruz Biotechnology, 
Heidelberg, Germany 
Gamma-H2AX(phospho S139) Ab26350 Abcam, Cambridge,  
U.K. 
GAPDH sc25778 Santa Cruz Biotechnology, 
Heidelberg, Germany 
Goat anti-rabbit lgG-HRP Sc-2004 Santa Cruz Biotechnology, 
Heidelberg, Germany 
Goat anti-mouse lgG-HRP Sc-2005 Santa Cruz Biotechnology, 
Heidelberg, Germany 
Goat anti-rabbit lgG-Rhodamin AP187R Merck KGaA, Darmstadt, 
Germany 
Goat anti-rabbit lgG-Fluorescein AP307F Merck KGaA, Darmstadt, 
Germany 
Materials and methods 
24 
Goat anti-mouse lgG-FITC AP181F Merck KGaA,Darmstadt, 
Germany 
2.1.6 Cell culture materials 
Table 6. Cell culture materials 
Type Company  
Cell culture flask T25 T75 Falcon, BD Bioscience, Heidelberg, Germany 
Cell culture 6 well, 12well, 96 well plate Falcon, BD Bioscience, Heidelberg, Germany 
Cell culture 96 well plate (white) Thermo Scientific, Denmark 
Cell culture 60mm2 dish Sarstedt, Nuembrecht, Germany 
Cell scraper Falcon, BD Bioscience, Heidelberg, Germany 
8-well chamber slides Falcon, BD Bioscience, Heidelberg, Germany 
Tubes 1.5ml or 0.5ml Eppendorf, Hamburg, Germany 
Pipette tips Eppendorf, Hamburg, Germany 
Polypropylene conical tube 15 ml, 50ml Falcon, BD Bioscience, Heidelberg, Germany 
Nitrocellulose Blotting Membrane GE Healthcare Life science, Freiburg, Germany 
Flow cytometry tube Falcon, BD Bioscience, Heidelberg, Germany 
Sterile pipettes Falcon, BD Bioscience, Heidelberg, Germany 
Syringe Filter Merck Millipore, Darmstadt, Germany 
Microscope slide Carl Roth, Karlsruhe, Germany 
2.1.7 Apparatus and software 
Table 7. Apparatus and software 
Apparatus or software Company 
BD FACS Canto II BD Becton Dickinson, Heidelberg, Germany 
Centrifugation  Eppendorf, Hamburg, Germany 
CO2 incubator  Heraeus GmbH, Hanau, Germany 
TCS SP2 Confocal microscope Leica, Wetzlar, Germany 
FlowJo software 10.1 Tree Star, Ashland, USA 
Fusion SL Vilber Lourmat, Eberhardzell, Germany 
GraphPad Prism 5.0 GraphPad Software, USA 
Immunofluoerscence optical microscopy Olympus, Hamburg, Germany 
Infinite M200 Tecan, Crailsheim, Germany 
Image J National Institutes of Health, Maryland, USA 
Inverted microscopy Zeiss, Oberkochen, Germany 
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Light microscope Leica, Wetzlar, Germany 
Linear accelerator ELEKTA, Crawley, U.K. 
2.2 Methods 
2.2.1 Cell culture 
The human glioblastoma cell line U251 cells (ATCC, LGC Promochem, Wesel, 
Germany) were cultured in RPMI1640 with 10% fetal bovine serum (FBS) and 1% 
penicillin-streptomycin. U87 cells (ATCC, LGC Promochem, Wesel, Germany) were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS and 1% 
penicillin-streptomycin. Cell cultures were incubated at 37°C in humidified 5% CO2 
incubators. Cells were trypsinized with 3xTrypsin/EDTA and passaged every 3 to 4 
days. Cells used in all experiments were within 12 passages. 
Floating U251 cells were collected from supernatant of U251 cells cultured as 
monolayer in serum-containing medium [159]. After centrifugation at 1200rpm for 5 
minutes, cells were washed with phosphate buffered saline (PBS). Then pellets were 
re-suspended in serum-free advanced DMEM/F12 medium containing 10% BIT 9500 
and 2mM L-glutamine supplied with 10ng/ml human recombinant epidermal growth 
factor (EGF), 10ng/ml human recombinant basic fibroblast growth factor (FGF-2) and 
1% penicillin-streptomycin, which was referred as defined serum-free medium. 
Sphere-like structures were formed 2-5 days of culture.  
The glioma stem-like cell line NCH644 was grown as neurospheres in defined serum-
free medium. Neurospheres were mechanically dissociated by pipetting to single cell 
suspension when they reached to around 200µm in diameter and split 1:5 to 1:9. In 
order to enrich for spheres, the entire content of culture flask was collected in conical 
tubes which were left at room temperature to allow spheres to settle down to the 
bottom of tube by gravity for 10 min. Then 1/2 to 3/4 of medium was removed and 
replaced with fresh complete medium. Medium was refreshed every 3-4 days by the 
method described above. 
Patient-derived glioma cells GBM46 and GBM48 were established from tumor tissues 
of patients with GBM (GBM46 glioblastoma WHO grade IV; GBM48 gliosarcoma 
WHO grade IV) after surgical resection at Medical Faculty Mannheim. Informed 
consent was obtained from both patients. Tumor cells were grown as monolayer in 
defined serum-free medium in plates pre-coated with poly-l-ornithine 
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(PLO)/fibronectin. Due to the different volumes of tissues obtained from surgery, 
growth rates of cells from each tumor were variable. Fresh medium was replaced 
every 4 days and cells were passaged when reaching confluent monolayer culture.  
2.2.2 Proliferation assay 
To explore the growth of U251 cells in different culture conditions, cells were 
harvested from exponential growth (U251-E) or plateau phase (U251-P) respectively, 
and re-seeded at high (8x104 cells/cm2) or low (2.4x104 cells/cm2) seeding density, 
defined relative to the standard cell culture density (4x104 cells/cm2) according to the 
previous study [91]. The schemes of parent culture and re-seeding culture were 
described in Table 8 and Table 9. Cells were detached by 3x Trypsin/EDTA at 
different time points. Cell numbers were counted by hemocytometer under 
microscope. The experiments were repeated in triplicate and the error bar 
represented standard error (SE). 
Table 8. Parent culture of U251 cells in exponential growth and plateau phase 
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To analyze the growth factor-stimulated proliferation of U251 cells, 2x 104 per well of 
cells were seeded in 12-well plate for 12-18h and starved in basal RPMI1640 
medium for 16-24h before different growth factors were added (shown in Figure 3). 
U251 cells from different days were fixed with 4% paraformaldehyde (PFA) for 15min 
at room temperature and stained with DAPI (1:1000 diluted in 1xPBS) for 5 min. Then 
DAPI solution was removed and PBS was added. The plates were covered by 
aluminum foil. Hereafter images were taken for different days by inversed 
fluorescence microscope. Ten bright field and DAPI staining images were captured 
from one side to the other along the diameter. Cell numbers were counted. All data 
were obtained by three independent experiments. 
 
Figure 3. Culture of U251 cells with different growth factors in 12 well plates. (FBS: 
10%; EGF: 20ng/ml; FGF-2: 20ng/ml; IGF-1 10: 10ng/ml; IGF-1 50: 50ng/ml; IGF-1 100: 
100ng/ml) 
To further test the optimal cell culture for proliferation of NCH644 cells, NCH644 cells 
were plated in serum-free DMEM/F12 medium as single cell suspension by 
mechanical segregation. After 16-24h starvation, different growth factors were added 
on day 0. Growth factors were added on day 3 and day 5 (shown in Figure 4). 
Images of NCH644 cells were taken from day 0 to day 6 and continually cultured at 
37°C in humidified 5% CO2 incubator. Images were captured by inversed 
fluorescence microscope. For each well, 10 bright field images were taken from one 
side to the other along the diameter. The number of spheres and area were analyzed 
by Image J software. The volume of spheres was calculated according to the formula: 
volume= (4/3) × pi × (area/pi)3/2. All data were obtained by three independent 
experiments. 
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Figure 4. Culture of NCH644 cells with different growth factors. (SFM: serum-free 
DMEM/F12 medium, 20ng/ml EGF, 20ng/ml FGF-2, 100ng/ml IGF-1) 
2.2.3 Detachment assay 
2.2.3.1 Harvest from attached monolayer culture 
Adherent U251 cells were washed with cold PBS twice and incubated with cold lysis 
buffer on ice. Lysates were directly harvested by scraping from cell culture plates with 
cell scraper referred as no-TE. 
2.2.3.2 Cell detachment with agents 
U251 cells were detached by different agents, including 3x Trypsin/EDTA, 
0.25%Trypsin, 0.06%EDTA and 200U/ml collagenase IV. Cells were incubated with 
trypsin or EDTA for 3min and collagenase IV for 2h with gentle pipetting at 37°C in 
humidified 5% CO2 incubator. After cell detachment, fresh medium was added and 
cells were re-suspended in 15ml conical tubes in incubator for indicated time. 
Thereafter, cells were washed with PBS once and harvested by centrifugation. The 
pellets were lysed with cold lysis buffer. 
2.2.3.3 Collection of conditioned medium  
U251 cells were detached by 3x Trypsin/EDTA. U251-E were re-suspended in 
RPMI1640 medium with 10% FBS. U251-P cells were re-suspended in basal 
RPMI1640 medium containing 1% BSA.  Suspended cells were cultured at 37°C in 
humidified 5% CO2 incubators for 1h. Then conditioned medium (CM) was harvested 
by centrifugation followed by passing through a 0.2µm-pore-diameter Millipore filter, 
referred to CM-detached. Supernatant collected from attached cells was filtered and 
referred to CM-attached.  
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2.2.3.4 Inhibitor assay 
For U251-E cells, cells were incubated with inhibitors and CM. Inhibitors were applied 
as followed: 10µM AG1024 and 10µM Erlotinib and 0.1%DMSO used as control. 
Cells were harvested at the indicated time points. For U251-P cells, cells were 
incubated with 10µM U0126, 10µM AG1024 and 10µM Erlotinib for 1h with and 
without CM. 
2.2.4 Western blotting 
Table 10. Separating and stacking gels  
Ingredient Separate gel (12%) Stack gel 
ddH2O 3.3 ml 1.4 ml 
30% acrylamide-bisacrylamide 4.0 ml 0.33 ml 
1.5M Tris (PH 8.8) 5.0 ml  
1.5M Tris (PH 6.8)                              0.25 ml 
10 % SDS  




0.004 ml                   
0.02 ml 
0.02 ml  
0.002 ml 
Cells were harvested at different time points and placed on ice. Cells were rinsed 
with cold PBS three times and lysed in cold RIPA buffer together with phosphatase 
inhibitor and protease inhibitor. Adherent cells were scraped using a cold cell scraper 
and lysates were transferred to 1.5 ml Eppendorf tube. For suspended U251 cells, 
lysates were harvested by centrifugation at 1200rpm for 5min and then washed with 
cold PBS once. Lysates were centrifuged at 14000rpm for 10min at 4°C and 
supernatants were transferred to new 1.5ml tubes. Thereafter protein concentration 
was determined by Bradford assay. Briefly, samples were diluted to 1:10 in aqua 
bidest (2µl sample added into 18µl aqua bidest) and 5µl of the mixture were loaded in 
a 96-well plate. Then 250µl 1x Bradford dye reagent was added into each well. Each 
sample was repeated in three wells. Binding of Coomassie Brilliant Blue G-250 dye to 
proteins converts the red-brown dye to blue. After incubation at room temperature for 
10 min, the blue dye was detected at 595 nm by microplate reader (Tecan). Bovine 
serum albumin standard were used for the standard curve (0.125, 0.25, 0.5, 1, 1.5, 
2mg/ml).  
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Cell lysates (15-20µg of total protein) were mixed with the same volume of 2x 
Lammaeli buffer with 5% β–mercaptoethanol. All samples were boiled for 5min at 
95°C and cooled down on ice for at least 5min before loading on a 12% SDS-PAGE 
gel (Table 10). 2µl of protein standard marker was also loaded. SDS-PAGE run at 
75V for 40min, and 120V for 100min. Hereafter proteins were electroblotted to the 
nitrocellulose blotting membrane at 300mA for 1 hour. The membrane was later 
blocked in 5% BSA in 1% TBS-T for 1 hour at room temperature, and subsequently in 
the following primary antibody at 4°C: anti-phospho-ERK1/2, anti-ERK1/2, anti-p27, 
anti-phospho-FAK Tyr397, anti-phospho-FAK Tyr925, anti-cleaved caspase 3, anti-
cleaved caspase 8, anti-caspase 8, anti-cyclin D1, anti-phosph-PLK1, anti-phospho-
JNK, anti-JNK and GADPH (1:1000 diluted in 5% BSA). After overnight incubation at 
4°C, membranes were washed with TBS-T three times for 10min and incubated for 1 
hour at room temperature with an appropriate goat anti-rabbit or goat anti-mouse 
IgG-HRP conjugates (1:20000 diluted in 1% TBS-T). The membranes were incubated 
with enhanced chemiluminescence (ECL) reagent (1:1 mixture of solution A and B in 
Western Lightning Plus ECL detection kit) for 1-2min in the dark at room temperature. 
Subsequently, immunoreactive bands were detected and visualized by 
chemiluminescence system (Fusion SL). Protein bands from western blot films were 
quantified using Image J. The intensity of each protein was normalized by dividing 
the corresponding loading control. The relative level of normalized protein was 
calculated as a ratio relative to the normalized control group.  
2.2.5 Caspase 3 activity 
Caspase-3 activity was tested using a colorimetric activity assay kit according to 
manufacturer’s instructions. Briefly, cells were washed with PBS and lysed in cold 
lysis buffer containing 50mM HEPES, 100mM NaCl, 0,1% CHAPS, 100µM EDTA, 
1mM DTT on ice. As shown in Table 11 below, 20µl cell extracts were added to 70µl 
assay buffer, followed by applying10µl fluorimetric substrate Ac-DEVD-AFC (50µg/ml 
diluted in assay buffer). Each sample was repeated in triplicate. After 1h incubation at 
room temperature in the dark, fluorescence was measured at 405 nm excitation and 
505 nm emission. Meanwhile, protein concentrations of cell extracts were measured 
by Bradford assay. The caspase3 activity was normalized with the absorbance 
intensity dividing the protein concentration and expressed as relative fluorescent 
units (RFU) per minute per mg protein for each condition. 
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Table 11. Reaction scheme for 96-well plate microassay method 
 Assay buffer Cell lysate Caspase 3 substrate  
Ac-DEVD-AFC 
Control 90µl - 10 µl 
Sample 70 µl 20 µl 10 µl 
 
2.2.6 Colony forming assay  
Cellular radiosensitivity was determined by clonogenic cell survival using the colony 
forming assay. U251 cells were harvested and sequentially diluted into desired 
concentrations in the concentrations 10 times higher than the number of cells seeded 
per flask (if 100 cells were seeded per T25, suspension of 1000cells/ml was 
prepared). The cell number and doses were shown in Table 12. Immediately before 
irradiation, 400µl suspensions of cells were centrifuged at 300g for 5min into a pellet 
at the tip of 0.5 ml Eppendorf tube. After irradiation, cells were re-suspended and 
100µl of suspensions were plated into T25 flask with 5ml fresh culture medium in 
triplicate. After incubation for 11 days, colonies were washed with PBS and fixed with 
1:3 methanol/acetic acid solution for 10 min followed by staining with crystal violet 
solution (1 g/l in aqua bidest). Colonies containing more than 50 cells were scored. 
The survival curve was analyzed with Linear-Quadratic (LQ) model using the 
SigmaPlot8.0 regression tool: SF(D)=exp[-(αD+βD2)]. Three independent 
experiments were performed.  
Table 12.  The cell number seeded in T25 flask with different doses 
U251 cells irradiated with 6MV X-rays   
Dose (Gy)   0  2 4 6  8 
Cell number 100     100 300 1000 3000  
2.2.7 Flow cytometry 
The nuclear antigen Ki67 is a proliferation marker present in proliferating cells 
throughout G1, S, G2 and M phase but absent in non-proliferating cells in G0 phase 
[160]. Propidium Iodide (PI) is a DNA binding dye most commonly used for cell cycle 
distribution based on the DNA content [161]. 
In order to explore cell cycle distribution and Ki67 expression of U251 cells in 
different conditions, 1x106 U251 cells were collected by trypsinization and transferred 
to 15 ml conical tubes followed by wash once with PBS. Then the pellet was re-
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suspended in 500 µl ice cold PBS and the suspension was slowly added drop wisely 
to 500 µl ice cold 2%PFA. After incubation on ice for 5min, cells were washed with 
1% BSA /PBS once and re-suspended in 500 µl of permeabilizing solution 0.25% 
Triton X-100 in PBS for 5min at room temperature. Cells were then washed with 1% 
BSA /PBS again and centrifuged at 1500rpm for 5min. The pellet was re-suspended 
in 100 µl PBS and cell mixture was transferred to 1.5ml Eppendorf tubes (at this step 
the cells can be stored at 4°C fridge until antibody staining). 5µl of anti-Ki67 antibody 
(Alexa Fluor® 647) was added, mixed and the mixture was incubated at room 
temperature for 1h in the dark. Afterwards, 1ml 1% BSA /PBS was added to tube and 
cells were centrifuged at 1500rpm for 5min. The supernatant was discarded carefully 
and cells were washed once with PBS. The pellet was re-suspended in 500µl PBS. 
Cell nuclei were stained with 2µg/ml PI following pretreatment with 50µg/ml RNAse 
and kept at room temperature for 30min in the dark. Flow cytometry was performed 
on a FACS Calibur and data analysis was performed using Flowjo version10 
software. 
2.2.8 Immunoflurescence 
Anti-Ki67 antibody was used to detect proliferating cells when U251 cells and 
NCH644 cells were grown as colonies or spheres. The plasma membrane protein 
CD133 and transcription factor SOX2 are markers associated with stemness. 
U251 and U87 cells were plated at 200 cells per well in 6-well plates. After 10-14 
days, colonies were formed and fixed with 4% PFA for 15min at room temperature. 
Then cells were blocked with 1% BSA in PBS with 0.3% Triton-X (PBST) for 20 min. 
Anti-Ki67 antibody (1:200 diluted in PBST) was applied for 1h at room temperature. 
Then cells were washed 3 times and incubated in the dark with second antibodies 
(Goat anti-rabbit lgG-HRP1:200 diluted in PBST). After 1h incubation, cells were 
washed with PBS three times. Then nuclei were counterstained with DAPI. Images 
were captured by inversed fluorescence microscope. 
Floating U251 cells and NCH644 spheres were seeded as single cells at the number 
of 1x104 in 12-well plates. Medium was refreshed by removing 250µl old medium and 
adding 250µl fresh medium every 2 days. On indicated days, cell suspension was 
plated on the slide pre-coated with poly-D-lysine for 3-4h to attach at room 
temperature and fixed with 4% PFA for 15 min. After blocking with 1% BSA in PBST 
Materials and methods 
33 
for 20min, cells were incubated with first antibodies (1:500 anti-CD133, 1:200 anti-
Ki67, 1:200 anti-SOX2) for 1h at room temperature. Then cells were washed three 
times with PBST and incubated in the dark with second antibodies (Goat anti-rabbit 
conjugated with Rhodamine 1:200 diluted in PBST; Goat ant-mouse conjugated with 
FITC 1:200 diluted in PBST) for 1h at room temperature. After three times washing 
with PBS, nuclei were counterstained with Draq5. Then mounting medium was added 
and a coverslip was put on the top. Images were captured by confocal microscope 
(Leica SP8). 
H2AX was used to examine radiation-induced DNA double-strand breaks (DSBs) 
repair foci. After irradiation of U251 cells in pellets, 1x104 cells were seeded in 8-well 
chamber slides and incubated at 37°C for attachment. At different time points after 
the end of irradiation, cells were washed, fixed and blocked as above. Thereafter, 
cells were incubated with primary antibodies (1:200 anti-H2AX) and then second 
antibodies (Goat ant-mouse conjugated with FITC 1:200 diluted in PBST). Finally, 
cells were sealed with Vectashield®mounting medium with DAPI and covered with 
coverslip. Cells were observed under fluorescence microscope and photographed. 
Foci were counted in each cell and 100 cells per well were analyzed. 
2.2.9 Statistics 
Results were shown as mean values ± standard errors (SE) or mean values ± 
standard deviation (SD). P values were calculated using Student’s t test for 






3.1 Effect of culture conditions on cell proliferation 
3.1.1 GBM cells undergo apoptosis under certain conditions 
In the previous work, Wang et al. showed that passage of exponentially growing 
U251 cells and re-seeding at high density resulted in complete downregulation of 
ERK1/2 phosphorylation at 12–36 h, whereas ERK1/2 activation was more strongly 
upregulated when U251 cells were harvested from plateau phase [91]. The results 
suggested that cell culture conditions including cell density have strong influences on 
ERK1/2 activity. In order to further investigate the functional implications of this 
paradox, cell proliferation in different re-seeding cultures was determined. U251 cells 
from exponential growth (U251-E) and plateau phase (U251-P) were re-seeded at 
high density (3.2x105cells/well) and low density (9.6x104cells/well) in 12-well plates 
and cultured for 3 days (Figure 5A). Cells were trypsinized and the numbers were 
counted by hemocytometer at different time points. As shown in Figure 5B, 
proliferation occurred when cells were re-plated at low density irrespective of the 
growth state of parent culture. Surprisingly, re-plating of U251-P cells at high density 
also resulted in further proliferation, consistent with the finding that releasing density-
arrest plateau phase cells provided upregulated mitogenic signaling, whereas re-
plating of U251-E cells at high density showed limited proliferation. 
To exclude the potential influence of growth factor depletion on this observation, the 
experiment was repeated with media change on day 2. This led to an enhanced 
proliferation of cells re-seeded at low density as well as U251-P cells at high density 
on day 2-4, further implying that ERK1/2 activity affected by changes in culture 
conditions has a profound mitogenic impact on U251 cell proliferation (Figure 5C).  
However, refreshing of the medium did not change the limited proliferation of U251-E 
cells when re-plated at high density (Figure 5C). The limited proliferation in EH cells 
was associated with cell detachment on day 3-4 as quantified by the number of 








Figure 5. Proliferation of U251 cells from different culture conditions. U251-E cells 
and U251-P cells were re-seeded at the density of 3.2x105cells/well and 9.6x104cells/well in 
12-well plates. Cell numbers were counted by hemocytometer at different time points. A. 
Images of U251 cells under different conditions on day 2. Scale bar=200 µm. B. Growth 
curve in four different groups without medium refreshed. C. Growth curve in four different 
groups with medium refreshed on the second day. D. The number of detached cells in four 
different groups. PH: cells harvested from U251-P and re-seeded at high density; EH: cells 
harvested from U251-E and re-seeded at high density; PL: cells harvested from U251-P and 
re-seeded at low density; EL: cells harvested from U251-E and re-seeded at low density. 







In order to test if the limited proliferation with detachment was associated with 
apoptosis, expression of cleaved caspase 3 and cleaved caspase 8 was analyzed by 
western blotting. Caspase activation was observed, as indicated by detectable 
cleavage of caspases 3 and 8 on day 2, suggesting that passage of exponentially 
growing cultures followed by re-seeding at high cell density resulted in programmed 
cell death (Figure 6A). The results were also confirmed by caspase 3 assay, which 
showed the increased activity of caspase 3 in EH cells compared with other groups 
(Figure 6B).  
 
 
Figure 6. Caspase assay in U251 cells from different culture conditions. A. Western 
blot analysis of apoptosis proteins, including caspase 8, cleaved caspase 8 and cleaved 
caspase 3 with GAPDH as control. B. Activity levels for caspase 3 in the four groups. Activity 
is expressed as RFU. PH: cells harvested from U251-P and re-seeded at high density; EH: 
cells harvested from U251-E and re-seeded at high density; PL: cells harvested from U251-P 
and re-seeded at low density; EL: cells harvested from U251-E and re-seeded at low density. 









To further test if this was a general phenomenon or limited to the U251 cell line, the 
same experiment was conducted with the patient-derived glioblastoma cells GBM46 
and GBM48. Similar to U251 cells, GBM46 and GBM48 cells from exponentially 
growing phase that were re-plated at high density showed an increased expression 
of cleaved caspase activation at 72h as confirmed by western blots and caspase 3 




Figure 7. Caspase assay in GBM46 and GBM48 cells from different culture 
conditions. A. Western blot analysis of apoptosis protein cleaved caspase 8 and cleaved 
caspase 3 in GBM46 cells. PH: cells harvested from plateau phase and re-seeded at high 
density; EH: cells harvested from exponential growth phase and re-seeded at high density. 
B. Activity levels for caspase 3 of of GBM46 cells at the indicated time points. Results of 
caspase 3 activity for GBM46 shown as means ± SD from one experiment. PH: cells 
harvested from plateau phase and re-seeded at high density; EH: cells harvested from 
exponential growth phase and re-seeded at high density. C. Western blot analysis of cleaved 
caspase 3 in GBM48 cells. D. Activity levels for caspase 3 of GBM48 cells at indicated time 












3.1.2 EH cells have G2 arrest and downregulation of cell cycle proteins 
To better understand the different phenotypic responses of exponentially growing 
and plateau phase cells, flow cytometry was performed to assess the cell cycle 
distribution and proliferation of U251 cells. DNA content was quantified by propidium 
iodide, while proliferating cells were detected with antibodies against proliferation 
marker Ki-67. Cell cycle histograms with G1, S and G2/M distributions characteristic 
of proliferating cells were seen on day 1 for all cultures, approximately 50-60% of the 
cells in G1, 15-20% in S, and 20-30% in G2. On day 3, however, plateau phase cells 
re-plated at high density were predominantly distributed in G1 (about 70%) and 15% 
in G2 phase with a significant fraction of non-proliferating (Ki67-low) cells in both 
phases. In contrast, Ki67-high EH cells accumulated in G2 (35%) while the G1 
fraction was reduced to 40% with only a small minority being Ki67-low. Although 
Ki67-low cells with sub-G1 DNA content were observed in both cultures, the fraction 
was high in EH cells. Furthermore, cells re-plated at low density showed slightly 
























Figure 8. Effect of different culture conditions on cell cycle distribution of U251 cells. 
A. Dot-Plot analysis of PI and Ki-67 staining in different groups on day 1 and day 3. B. 
Proportion of cells in different cell cycles and Ki67 expression. Results are shown as means 








Since re-seeding exponentially growing cells at high density resulted in G2 
accumulation, the expression of cell cycle regulating proteins was investigated by 
western blotting. Phosphorylation of ERK1/2 showed strong, transient 
downregulation in EH cells 24h after re-plating (Figure 9A), similar to the previous 
study [91]. Expression of cyclin D1 was lower in EH than in PH cells at all time points 
and was increasingly downregulated in EH cells at 24h and 48h, consistent with the 
observed inhibition of cell proliferation from day 2 (Figure 5B, C). Phosphorylation of 
PLK-1 which is required for entry into mitosis was strongly down-regulated in EH cells 
at 48h (Figure 9A, B). This was consistent with the accumulation of cells in G2 phase 
(Figure 8B). Furthermore, the expression of p27 was upregulated in EH cells at 24h 




Figure 9. Western blot analysis of cell cycle proteins of U251 cells. A. Western blot 
analysis of expression of p-ERK, cyclin D1, p-PLK1 and p27 with GAPDH as control. B. 
Densitometric analysis of the western blot intensity of the indicated proteins shown in Fig.9A, 
normalized to GAPDH. PH at 24h was used as reference. Results are shown as means ± SE 
from at least three independent experiments.* represents P< 0.05; ** represents P< 0.01;*** 





Moreover, in the patient-derived GBM46 and GBM48 cells, expression of cyclin D1 
was decreased in EH cells compared with PH cells, accompanied by decreased 




Figure 10. Western blot analysis of cell cycle proteins of GBM46 and GBM48 cells. 
Western blot analysis of expression of p-ERK, cyclin D1 and p27. GAPDH as control. 
3.1.3 Effect of FAK on EH cell apoptosis 
To test if FAK activation is altered with respect to changes in culture conditions, the 
expression of FAK phosphorylation was detected by western blotting. The best-
characterized FAK phosphorylation event is the autophosphorylation at Y397, further 
leading to phosphorylation of other tyrosine residues including Y925 [162]. Western 
blots showed that FAK phosphorylation at Y397 was significantly lower in EH cells at 
6h compared with PH cells and remained reduced at 24h and 48h. In contrast, FAK 
phosphorylation at Y925 was only moderately reduced in EH at 6-24h compared with 








Figure 11. FAK expression in different culture conditions in U251 cells.  A. Western 
blots analysis of p-FAK-397 and p-FAK-925 with GAPDH as control. B. Densitometric 
analysis of the western blot intensity of the indicated proteins shown in Fig.11A, normalized 
to GAPDH. PH at 24h was used as reference. Results are shown as means ± SE from at 
least three independent experiments.* represents P< 0.05; ** represents P< 0.01; *** 
represents P< 0.001. 
Because activated FAK expression was decreased and loss of attachment might 
downregulate this pathway, it was assumed that increasing FAK expression might 
rescue apoptosis when exponentially growing cells were re-plated at high density. It 
has been documented that growth factors as well as EMC can increase the 
expression of FAK [163]. Thus, U251 cells were seeded in plates coated with 
0.83mg/ml collagen I or 10µg/ml fibronectin and supplied with growth factors 
100ng/ml IGF-1 and 10ng/ml TGFβ. However, EH cells were not rescued from 





downregulation of FAK signaling pathways is not responsible for the decreased p-




Figure 12. Effect of increasing FAK on cell apoptosis.  U251-E cells were re-plated at 
high density in fibronectin pre-coated plates.  Protein lysates were harvested at the indicated 
time points. Western blot analysis of p-FAK-397, cleaved caspase 3, cleave caspase 8 and 
p-ERK1/2 with GAPDH as control. FN: plates pre-coated with fibronectin. B. U251-E cells 
were re-plated at high density in collagen I pre-coated plates or adding growth factors. 
Western blot analysis of p-FAK-397, cleaved caspase 3, cleave caspase 8 and p-ERK. 
GAPDH as control. Collagen I: plates pre-coated with 0.83mg/ml collagen I. IGF-1 100ng/ml; 
TGF-β: 10ng/ml.  
3.1.4 Effect of upregulation of p27 on EH cell apoptosis 
To test the possible involvement of cell cycle progression, p27 in exponentially 
growing cells was induced to upregulate by starvation before the re-seeding 
experiment. As shown in Figure 13A, U251-E cells had increased expression of p27 
after 24h starvation, resulting in cell cycle arrest. Then, U251-E were incubated with 
0.5% FBS medium for 12h and re-seeded at high density in the same low FBS 
medium referred as 0h. After another 12h incubated in 0.5% FBS medium, medium 
was refreshed with 10% FBS medium and cells were collected at the indicated time 





caspase by western blot (Figure 13B). Moreover, starved U251-E cells survived and 
continued to proliferate with no obvious detachment after re-plating at high density 
(Figure 13C). The results demonstrated that upregulation of p27 prevents cells from 
undergoing apoptosis, suggesting that uncontrolled cell cycle progression plays a 




Figure 13. Effect of P27 upregulation on cell apoptosis.  A. Western blot analysis of p27 
and p-ERK with GAPDH as control. U251-E cells were cultured in basal RPMI medium for 
6h, 12h and 24h. B. Western blot analysis of p27, cleaved caspase 3 and cleaved caspase 8 
with GAPDH as control. U251-E cells in basal medium with 0.5% FBS were starved for 12h 
and re-seeded at high density. After 12h, medium was changed with 10% FBS as 0h and 
cells were collected at the indicated time points. C. Growth curve of EH cells after starvation. 






3.2 The balance between ERK1/2 and JNK activation in parent cultures 
3.2.1 ERK1/2 activation in parent cultures 
Since downregulation of activated ERK1/2 preceded caspase activation at 48h, the 
assumption was made that programmed cell death after exponentially growing cells 
reseeded at high cell density might be induced by downregulation of p-ERK1/2,  
causing blockage of cell entry into mitosis. In order to explore the underlying 
mechanisms of downregulation of activated ERK1/2 after re-plating of exponential 
growth cells at high density, ERK1/2 activation in U251-P and U251-E cells was 
detected by western blots.  
Firstly, parent cell cultures were tested by harvesting from attached monolayer 
culture or cell lysis after cell detachment. Western blots showed low activation of 
ERK1/2 and upregulated expression of p27 in U251-P cells by directly scraping cells 
from substrate (Figure 14). Interestingly, cells in U251-P had a robust activation of 
ERK1/2 immediately after loss of cell adhesion while the high level of p27 expression 
was not affected. When cells were treated with different incubation time of 
trypsin/EDTA, the strong activation of ERK1/2 was still observed in U251-P cells 
(Figure 14). On the other hand, U251-E cells showed a higher basal level of ERK1/2 
activation and low p27 expression when directly scraping cells from substrate, 
indicating the mitogenic signature of proliferating cells. However, the levels of 
activated ERK1/2 remained unchanged after cell detachment using different 
incubation time or concentrations of trypsin/EDTA (Figure 14).   
 
Figure 14. ERK1/2 activation after cell detachment by trypsinization in parent cell 
cultures of U251 cells.  U251-P and U251-E cells were directly scraped from substrate (no-
TE) or trypsinized with different incubation time or concentrations of trypsin/EDTA (TE). The 




Next, the effect of cell detachment in a long time course on ERK1/2 activation was 
tested. U251 cells in both phases were detached by trypsinization and kept re-
suspended in fresh medium. Lysate collected immediately after trypsinization was 
referred as 0h. Cells in suspension were incubated for indicated time points when 
lysates were harvested. In U251-P cells, upregulation of ERK1/2 activation was seen 
immediately after cell detachment and sustained for at least 6h in suspension. The 
activation of ERK1/2 in U251-E cells remained high after cell detachment but 
decreased in cell suspension incubated for 1h (Figure 15). To be noted, FAK 
phosphorylation at Y397 was undetectable after loss of adhesion in both parent 
cultures (Figure 15). This result was consistent with other findings that 
phosphorylation of FAK at Y397 required cell attachment [164], further suggesting 
that activation of ERK1/2 is FAK independent. 
 
 
Figure 15. ERK1/2 activation in suspension after detachment in parent cell cultures of 
U251 cells. U251-P and U251-E cells were directly scraped from substrate (no-TE) or 
trypsinized and incubated in suspension for indicated time points. The expression of p-
ERK1/2, ERK1/2, p27 and p-FAK was detected by western blots with GAPDH as control. 
Finally, in order to test whether upregulation of ERK1/2 activation was an artifact of 
trypsinization, different agents were used for cell detachment. Collagenase IV is 
believed to be relatively gentle to preserve the integrity of cell membrane receptors 
[165]. Different agents were used for cell detachment, including 3xTE, 0.25% trypsin, 
0.06% EDTA and 200U/ml collagenase IV. As shown in Figure 16, ERK1/2 activation 
was not affected using different agents for cell detachment, suggesting that it was 
due to loss of cell attachment rather than an artifact of trypsinization (Figure 16). 
Taken together, these results demonstrated a fundamental difference in ERK1/2 




Figure 16. ERK1/2 activation after cell detachment using different agents in parent cell 
cultures of U251 cells.  U251-P and U251-E cells were directly scraped from substrate (no-
TE) or detached with different agents. The expression of p-ERK1/2, ERK1/2 and p27 was 
detected by western blots. GAPDH as control. 3xTE: 0.15% trypsin and EDTA; T: 0.25% 
trypsin; E: 0.06% EDTA; C: 200U/ml Collagenase IV. 
3.2.2 The regulation of ERK1/2 and JNK activation 
JNKs have been identified to play context-dependent roles in both cell proliferation 
and apoptosis. To test if JNK was involved in apoptosis in EH cells, JNK activation 
was detected. Harvesting U251-E cells before re-seeding was referred as 0h. As 
shown in Figure 17A and 17B, the upregulated expression of activated JNK was 
inversely related to the decreased ERK1/2 activation in EH cells. However, activation 
of JNK was prevented by re-plating of starved U251-E cells at high density, 
accompanied by upregulation of ERK1/2 activation (Figure 17C). The results 
suggested that increased JNK activation along with decreased ERK1/2 activation 
was involved in cell apoptosis, which was inversed by upregulation of cell cycle 







Figure 17.  JNK activation in EH cells.  A. Western blot analysis of p-ERK1/2, p-JNK with 
GAPDH as control. After re-plating U251-E cells at high density, cells were harvested at 
different time points. B. Densitometric analysis of the western blot intensity of the indicated 
proteins shown in Fig.17A, normalized to GAPDH. 0h was used as reference. Results are 
shown as means ± SE from two independent experiments. C. Western blot analysis of p-
ERK1/2, p-JNK with GAPDH as control. U251-E cells in basal RPMI medium with 0.5%FBS 
were starved for 12h and re-seeded at high density. After 12h, medium was changed with 
10%FBS as 0h and cells were collected at the indicated time points.  
Next, JNK and ERK1/2 activation were investigated in U251 parent cultures. U251-E 
and U251-P cells were exposed to conditioned medium (CM) from detached and 
attached cells. Western blots showed that U251-P cells had upregulated ERK1/2 
activation but not JNK when exposed to CM from detached U251-P cells, while no 
striking upregulation of ERK1/2 or JNK activation was observed when exposed to CM 
from attached U251-P cells (Figure 18A, B). In contrast, U251-E cells exposed to CM 
from detached U251-E cells exhibited downregulation of p-ERK1/2 while expression 
of JNK activation was upregulated, which was not seen when exposed to CM from 
attached U251-E cells (Figure 18C, D). The results indicated that a transferrable 
factor in CM from detached U251-P cells upregulated ERK1/2 activation, while 
factors in CM from detached U251-E cells inhibited ERK1/2 activation but induced 






















Figure 18. JNK and ERK1/2 activation in parent cell culture.  A. Western blot analysis of 
p-JNK and p-ERK1/2 in U251-P cells exposed to conditioned medium from detached U251-P 
cells and attached U251-P cells at the indicated time points. Cells were harvested by 
scraping from the plates. no-CM: cells without medium change; 0h: lysates collected after 
immediately medium change. 1h-16h: cells were harvested after incubation with medium 
change for indicated time points. B. Densitometric analysis of the western blot intensity of the 
indicated proteins shown in Fig.18A, normalized to GAPDH. no-CM was used as reference. 
Results are shown as means ± SE from two independent experiments. C. Western blot 
analysis of p-JNK and p-ERK1/2 in U251-E cells exposed to conditioned medium from 
detached U251-E cells and attached U251-E cells at the indicated time points. D. 
Densitometric analysis of the western blot intensity of the indicated proteins shown in 
Fig.18C, normalized to GAPDH. no-CM was used as reference. Results are shown as means 
± SE from three independent experiments. 
To further investigate which pathway or transferrable factors might be involved, 
different inhibitors were applied. U251-P cells were incubated with original medium 
(no-CM), basal RPMI1640 medium with 1% BSA (BSA) or conditioned medium from 
detached U251-P cells (CMD). Then 10µM MEK inhibitor U0126, 10µM EGFR 
inhibitor Erlotinib and 10µM IGF-1R inhibitor AG1024 were added to medium, 
respectively. Cells were harvested after 1h incubation. 0.1% DMSO was used as 
control. Western blots showed that CMD-induced ERK1/2 upregulation was 
abolished by MEK inhibitor U0126 but the other two inhibitors had no effect (Figure 
19A, B). These results suggested ERK1/2 activation in detached U251-P cells was 
mediated via intracellular signaling to MEK and ERK1/2 in an autocrine mechanism 











Figure 19. ERK1/2 activation induced by CMD in plateau phase cells.  A. Western blot 
analysis of p-ERK and ERK with GAPDH as control. U251-P cells exposed to CMD with or 
without 10µM U0126, Erlotinib and AG1024. 0.1% DMSO was used as control. Cells were 
harvested by scraping from the plates. no-CM: cells without medium change; BSA: U251-P 
cells exposed to basal RPMI1640 medium with 1% BSA; CMD:  U251-P cells were detached 
by 3xTE and re-suspended in basal RPMI1640 medium with 1% BSA. Conditioned medium 
was collected after 1h incubation. B. Densitometric analysis of the western blot intensity of 
the indicated proteins shown in Fig.19A, normalized to GAPDH. no-CM was used as 
reference. Results are shown as means ± SE from three independent experiments. * 
represents P< 0.05; **represents P< 0.01. 
U251-E cells were incubated with conditioned medium from detached U251-E cells. 
10µM Erlotinib and AG1024 were added to medium respectively and 0.1% DMSO 
was used as control. Cells were harvested at different time points. As shown in 
Figure 20, CM from detached U251-E cells induced increased expression of p-JNK 
and IGF-1R inhibitor AG1024 significantly inhibited JNK activation (P< 0.05). 
However, EGFR inhibitor Erlotinib had no effect. The results suggested that JNK 
activation is partially mediated via IGF-1R signaling in exponentially growing cells 







Figure 20. JNK activation induced by CMD in exponential growth phase cells.  A. 
Western blot analysis of p-JNK and JNK with GAPDH as control. U251-E cells were exposed 
to CM with or without 10µM Erlotinib and AG1024 for indicated time points. 0.1% DMASO 
was used as control. no-CM: cells without medium change; CM from detached U251-E: 
U251-E cells were detached by 3xTE and re-suspended in RPMI1640 medium with 10% 
FBS. Conditioned medium was collected after 1h incubation. B. Densitometric analysis of the 
western blot intensity of the indicated proteins shown in Fig.20A, normalized to GAPDH. no-
CM was used as reference. Results are shown as means ± SE from four independent 
experiments. * represents P< 0.05. 
3.3 Radiation response of U251 cells from different parent cultures 
3.3.1 Clonogenic survival of U251 cells from different parent cultures 
The previous data demonstrated different regulation of ERK1/2 and JNK activation 
after loss of attachment of U251-E and U251-P cells. Thus, it was assumed that such 
differences had effects on radiation response of U251 cells upon detachment. To 
characterize the radiation sensitivity of U251 cells from different parent cultures, 
colony forming assay was performed. As shown in Figure 21A, the clonogenic 
survival curves were very similar for immediate plating of cells from plateau and 
exponential growth phase. However, surviving fraction at 2Gy (SF2) in cells from 
U251-P was significantly higher than that in cells from U251-E (0.76 ± 0.02 vs. 0.66 ± 
0.03, P< 0.01), whereas no significance was found regarding surviving fraction at 







Figure 21. Clonogenic cell survival curve of U251 cells from different parent cultures. 
A. The surviving fraction of colony-forming U251 cells versus dose was fitted by LQ model in 
three independent experiments. B. Surviving fraction at different doses in both groups. ** 
represents P< 0.01. ns. represents P> 0.05. Results are reported as means ± SD obtained 
from three independent experiments. 
Table 13. Values of the coefficients, α and β, and SF obtained from the LQ model 
fitted survival curves 
 from U251-E from U251-P 
α (Gy-1) 0.168 ± 0.038 0.072 ± 0.043 
β(Gy-2) 0.048 ± 0.005 0.064 ± 0.005 
SF(2) 0.66 ± 0.03 0.76 ± 0.02 
SF(4) 0.25 ± 0.04 0.28 ± 0.07 
SF(6) 0.06 ± 0.02 0.07 ± 0.02 







3.3.2 Induction and decay of DSBs after irradiation 
Next, DSBs repair capacity of U251 cells from different cultures was determined by 
detecting H2AX foci formation. The morphology at different time points after different 
doses of irradiation was shown in Figure 22. Without irradiation, U251 cells from both 
cultures showed a low background of foci per cell at each time point. Irradiation-
induced foci formation was scored by subtracting the background of corresponding 
non-irradiated cells. The kinetics of induction and decay of H2AX foci were similar in 
each group. The majority of foci were formed 1h post irradiation and most of foci 
disappeared up to 24h in all groups (Figure 23A). However, the number of H2AX 
foci per cell was significantly higher in cells from U251-P than from U251-E induced 
at 1h and 3h after 2Gy irradiation (1h: 27.81 ± 2.62 vs. 19.96 ± 0.58, P< 0.01; 3h: 
22.52 ± 0.74 vs. 18.15 ± 1.16, P< 0.01, respectively). After 24h, residual foci number 
did not significantly differ (3.70 ± 1.46 vs. 3.03 ± 0.99, P> 0.05). The results 
suggested that more DSBs induced by 2Gy irradiation were repaired in cells from 
U251-P. When cells were exposed to a large dose of 8Gy, no significance of foci 
number per cell was observed (1h: 61.57 ± 2.89 vs. 58.98 ± 6.52, P> 0.05; 3h: 57.54 
± 3.03 vs. 58.86 ± 6.52, P> 0.05; 24h: 8.32 ± 1.59 vs. 7.24 ± 0.53, P> 0.05, 





Figure 22. Images of H2AX repair foci in different time points post irradiation in U251 
cells from different parent cultures. U251 cell pellets were exposed to 2Gy and 8Gy 6MV 
X-rays and seeded in 8 well chambers. Cells were fixed 1h, 3h and 24h after the end of 






Figure 23. H2AX foci number per cell in response to irradiation. A. The kinetics of 
H2AX foci in U251 cells from different cultures exposed to 2Gy and 8Gy with 6MV X-rays. B. 
Analysis of H2AX foci number per cell in U251 cells from different cultures exposed to 2Gy 
and 8Gy with 6MV X-rays. For each condition in one experiment, 100 cells were scored to 
detect foci number per cell. Results are shown as means ± SD from three independent 
experiments. ** represents P< 0.01; ns. represents P> 0.05. 
3.4 Effect of different growth factors on proliferation of GBM cells in vitro 
The results presented above and in the previous study by Wang et al. strongly 
suggest the growth and proliferation of glioblastoma cells are highly regulated 
processes which depend on growth states of parent cultures. This was further tested 
by characterizing minimal growth factor requirements of the U251 cells line and 
NCH644 primary cells. 
Exogenous growth factor alone can barely support the proliferation of U251 cells 
when they were cultured in EGF and FGF-2 at 20ng/ml which is the proper 
concentration in medium of glioma stem cell, whereas IGF-1 showed dose-
dependent stimulation of U251 cells (Figure 24A, B). Combining IGF-1 with FGF-2 
resulted in proliferation approaching that seen for FBS in contrast with the 














Figure 24. Effect of different growth factors on proliferation of U251 cells. A. Images of 
U251 cells cultured in single growth factors and 10% FBS. Nuclei were stained with DAPI. 
Scale bar=200µm. B. Growth curve of U251 cells cultured in single growth factors and 10% 
FBS. C. Representative images of U251 cells in combined growth factors and 10% FBS. 
Nuclei were stained with DAPI. D. Growth curve of U251 cells stimulated in different 
combinations of growth factors compared with 10% FBS. Results are shown as means ± SE 
from three independent experiments. 
D




The human stem cell-like glioma NCH644 cells grew in defined serum-free medium 
and were passaged by mechanical dissociation. Although single growth factor only 
supported moderate proliferation, FGF-2 was slightly more effective than EGF and 
IGF-1 (Figure 25A, B). However, combining all three growth factors supported 
efficient proliferation while the combination of FGF-2 and EGF was better than other 
combinations of two growth factors (FGF-2+IGF-1 or EGF+IGF-1: Figure 25C,D). 









Figure 25. Effect of different growth factors on proliferation of NCH644 cells.  A. 
Images of NCH644 cells in different growth factors. Scale bar=100µm.B. Growth curve of 
NCH644 cells cultured in single growth factor. C. The growth curve of NCH644 cells cultured 
in different combinations of mitogens. Results are shown as means ± SE from three 
independent experiments. 
3.5 Contact inhibition retained in glioblastoma cells in vitro 
As shown above cells in plateau phase cultures showed low ERK1/2 activation but 
high levels of p27 expression (Figure 14). This inverse relationship suggested that 
some degree of density arrest may remain operative in U251 cells. Low numbers of 
U251 cells and U87 cells were seeded in clonal cultures, and cultured for several 
days to form colonies. Cells were stained with proliferative marker Ki67 and nuclear 
was counterstained with DAPI.  In the colonies, Ki67 was expressed mainly in cells at 
the periphery, supporting the hypothesis that cell-cell contact in the inner part of the 
colony inhibits cells proliferation. Similar results were obtained with colonies formed 






Figure 26. Immunostaining of U251 and U87 colonies.  Colonies of U251 and U87 cells 
were stained with Ki67 and nuclei counterstained with DAPI. Scale bar=100µm. 
Because cells in spheres show more cell-cell contacts growing surrounded by other 
cells in all directions compared with adherent cell culture, the experiment was also 
conducted with U251 spheres cultured in defined serum-free medium containing EGF 
and FGF-2. Single stem-like U251 cells were seeded and cultured as spheres which 
were harvested at the indicated time points. After 12 days of culture, spheres were 
split into single cells and re-seeded. Cells were stained with stem cell marker SOX2 
and proliferative marker Ki67. On day 2 and day 5, spheres were small and most of 
cells were Ki67 positive. On day 9 and day 12, the proportion of Ki67 positive cells 
was decreased in large spheres and Ki67 negative cells were observed mainly in the 
inner part of spheres. Cells positive for the stem cell marker SOX2 were found in both 
Ki67 positive and negative cells in the spheres (Figure 27A). However, re-plating of 
dispersed large spheres at lower density resulted in upregulation of Ki67 in the small 
Results 
62 
spheres but again Ki67 negative cells were detected in the inner part of large 






Figure 27. Immunostaining of U251 spheres.  A. Images of U251 spheres after seeding 
single cells in defined serum-free medium. Spheres were collected on day 2, day 5, day 9 
and day 12 and labelled with SOX2 and Ki67 and nuclei counterstained with Draq5. B. 
Images of U251 spheres after re-plating single cells from the dissociated spheres. Spheres 
were collected on day 2, day 5, day 9 and day 12 and labelled with SOX2 and Ki67 and 
nuclei counterstained with Draq5. Two different layers of the same sphere are displayed. 




In order to see this phenomenon in primary glioblastoma, the experiment was 
repeated with primary NCH644 cells. Single NCH644 cells formed small 
neurospheres, in which all cells were Ki67 and CD133 positive. After 9 days of 
culture, Ki-67 positive cells were found predominantly near the surface of big 
neurospheres of these cells. Similar to SOX2 expression in U251 spheres, the stem 
cell marker CD133 positive staining did not co-localize with Ki-67 positive cells but 
was found also inside the neurospheres in areas with low Ki-67 (Figure 28A). After 
re-seeding neurospheres as single cells, cells in the smaller spheres expressed Ki67 








Figure 28. Immunostaining of NCH644 neurospheres.  A. Images of spheres of primary 
NCH644 cells after single cells seeded. Spheres were collected on day 3, day 5, day 9 and 
day 12. Spheres were stained with CD133, Ki67 and Draq5. B. Images of spheres of primary 
NCH644 cells after re-plating single cells from the dissociated spheres. Spheres were 
collected on day 1, day 5, day 9 and day 12. Spheres were stained with CD133, Ki67 and 





GBM cells display the features of apoptosis resistance and aggressiveness due to 
loss of tumor suppressor genes PTEN, RB and p53, and amplification of growth 
factor receptors such as EGFR and IGF-1R [166, 167]. In addition, alterations of pro-
survival and anti-apoptosis pathways play important roles in gliomagenesis and 
response to therapies [168]. In a previous study, Wang et al. have shown 
upregulation of mitogenic signaling when U251 cells were released from density-
arrest plateau phase, even when they were re-seeded at high density, while this 
observation was not seen when exponential growth phase cells were re-seeded at 
high density. These results suggested ERK1/2 activity was influenced by changes in 
culture conditions including cell density as well as the growth state of parent culture. 
In agreement with their findings, a major result of the present study was that the 
strong mitogenic signaling led to increased proliferation upon re-plating of U251-P 
cells at high density, whereas ERK1/2 downregulation led to limited proliferation with 
cell apoptosis when re-plating of U251-E cells at high density. In addition, the 
mechanisms underlying ERK1/2 activation were investigated further. A fundamental 
difference of ERK1/2 and JNK regulation was observed in parent cultures, suggesting 
the balance of these two signaling pathways plays an important part in proliferation 
and survival of GBM cells. Besides, the present study highlighted the role of 
functional cycle-dependent kinase inhibitors in growth of GBM cells coordinated with 
mitogenic signaling.  
4.1 Role of FAK in regulating apoptosis 
It has been reported migrating glioma cells are less prone to apoptosis, which is 
attributed to the altered interaction with ECM and modifications of adhesion 
molecules [169]. The present results showed that re-plating of U251-E cells at high 
density resulted in limited proliferation accompanied by cell detachment, which was 
confirmed as apoptosis by caspase activation. The special type of programmed cell 
death with cell detachment is termed anoikis. Due to the association with cell integrin-
ECM interaction, aniokis has been reported to be suppressed by activation of integrin 
signaling. In primary rat hepatocyte cultures, matrigel abolished spontaneous 
apoptosis with cell detachment, which was triggered by high density culture [170]. In 
GBM, integrin inhibition-induced glioma cell death with detachment can be rescued 
by the addition of recombinant transforming growth factor-β (TGF-β), which promotes 
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survival downstream of integrin signaling [171]. This cell matrix-dependent regulation 
of apoptosis may be mediated by FAK activation upon integrin binding to ECM. The 
importance of FAK signaling in anoikis suppression and cell survival has been 
documented. Kurenova et al. reported that FAK activation provided a survival signal 
by binding to the death domain kinase receptor-interacting protein [172]. Besides, 
Bouchard et al. showed FAK/SRC signaling can promote cell growth in a cell 
detached condition via activation of PI3K/AKT and MAPK/ERK1/2 signaling pathways 
[173]. In addition, activation of FAK induced by collagen type I has been reported to 
contribute to tumor migration, invasion and progression [174, 175]. However, in the 
present study, increasing FAK expression did not show the hypothesized suppressive 
effect on apoptosis when exponentially growing U251 cells re-plated at high density. 
The data suggested the downregulation of FAK was not the cause of apoptosis but 
the consequence of apoptosis-induced cell detachment. Moreover, downregulation of 
ERK1/2 was not reversed when cells seeded on ECM coated plates or adding 
exogenous growth factors, further indicating that FAK dysregulation was not 
responsible for decreased expression of p-ERK1/2. Although ERK1/2 has been 
suggested as a downstream effector of FAK signaling [176], the role of FAK 
regulating ERK1/2 activity still remains controversial. In normal fibroblasts, FAK 
activation was required for integrin-growth factor synergy pathway to activate ERK1/2 
cascade [177]. Besides, enhanced FAK activation was observed to contribute to the 
adhesion and invasion of pancreatic cancer cells through ERK1/2 signaling pathway, 
when cells were plated on collagen type IV and stimulated with Interleukin-1α [178]. 
In contrast, Barberis et al. proposed that FAK was not necessary for efficient tyrosine 
phosphorylation of Shc and activation of ERK1/2 upon matrix adhesion in primary 
fibroblasts [179]. The discrepancy could be attributed to cell type dependency as well 
as the compensation from other integrin-mediated downstream effectors including 
Pyk2 and p130Cas [180, 181]. Taken together, despite of some limitations regarding 
the efficiency of increasing FAK expression, the mechanism in this case is not FAK 
signaling dependent. 
4.2 Role of ERK1/2 and JNK activation in GBM 
4.2.1 Regulation of ERK1/2 and JNK 
In the previous work, Wang et al. showed different basal levels of ERK1/2 activation 
after re-plating of U25 cells from plateau and exponential growth phase [91]. Thus, 
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when ERK1/2 activity was studied in parent cultures of U251 cells, a fundamental 
difference in ERK1/2 regulation was observed between different parent cultures. 
U251-P cells with low basal levels of ERK1/2 had strong ERK1/2 activation after loss 
of attachment and the strong ERK1/2 activation was sustained for several hours in 
suspension, which provided mitogenic signaling involved in the increased 
proliferation upon re-plating of U251-P cells at high and low density. Consistent with 
the present data, Al-Ayoubi et al. found ERK1/2 activation was strongly upregulated 
after cell detachment from substrate in ovarian cancer cell lines but not in benign 
ovarian cell lines [182]. 
Given that trypsin is reported to stimulate MAPK signaling pathway [183], the effect of 
trypsinization should be taken into account. As the major traditional cell removal 
method, trypsinization is pointed out to have effects not only on cell morphology but 
on ECM proteins remaining at cell surface [184]. There is evidence that cold trypsin 
can be used to quench cell signaling. In a cold trypsin-phosphorylation-specific flow 
cytometry protocol, the basal pERK1/2 levels remained low using cold trypsin 
compared with trypsinization at 37°C [185]. In order to test if ERK1/2 activation was 
an artifact of trypsinization, different agents for cell detachment were compared 
including collagenase IV which is considered to be relatively gentle to preserve the 
integrity of cell membrane receptors. Activation of ERK1/2 was not affected in both 
parent cultures, strongly supporting that activated ERK1/2 in U251-P cells was due to 
loss of cell attachment rather than trypsinization. This notion was also confirmed by 
other groups. Zhao et al. showed that Hippo signaling was activated following cell 
detachment within 10min by either trypsin or EDTA, while direct lysis of the attached 
cells had no effect [186]. Liu et al. demonstrated cell detachment by different 
enzymes, calcium depletion and mechanical methods resulted in activation of Notch1 
signaling in non-small cell lung cancer cell lines as well as breast cancer MCF7 cells 
and prostate cancer LnCap cells [187]. These results indicated that numerous 
signaling pathways are activated after cell detached from ECM. The possible 
mechanism may be attributed to autocrine activation, cell-matrix interaction leading to 
the cleavage of receptors, or cytoskeleton organization [188]. The current results 
demonstrated that a soluble factor produced by detached cells might stimulate 
intracellular signaling to MEK and ERK1/2 in an autocrine fashion, consistent with the 
study by Al-Ayoubi et al. [182]. To be noted, blockage of EGFR and IGF-1R did not 
inhibit ERK1/2 activation, indicating neither pathway plays a dominant role in ERK1/2 
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regulation upon cell detachment. Several explanations are summarized as followed. 
First, Wang et al. found IGF-1R was responsible for FBS-induced ERK1/2 activation 
in U251 cells [91]. However, in this study, ERK1/2 activation was induced by 
conditioned medium from detached U251-P cells without FBS, in which case IGF-1R 
might have a minor effect. Thus, it is possible that the IGF-1R pathway mediates 
ERK1/2 activation in response to FBS, leading to mitogenic effects on U251 cell 
proliferation. Second, other vital signaling pathways may also be involved. In anoikis-
resistant lung tumor cells, elevated Src activity was observed upon cell detachment, 
which was critical for cell survival in suspension. And Src activation may be mediated 
via PDGFR signaling [189]. Moreover, the crosstalk and compensatory effects of 
signaling pathways contribute to the complex ERK1/2 regulation. Therefore, the 
observation needs to be extended to find involved signaling pathways in ERK1/2 
activation. 
On the other hand, in the present study, the relative high basal level of p-ERK1/2 
remained unchanged following loss of cell attachment but was decreased in 
suspension in U251-E cells. Although the detailed mechanism of ERK1/2 
downregulation is not elucidated by now, lack of ERK1/2 activation in detached 
U251-E cells may contribute to anoikis after re-plating at high density. The critical role 
of ERK1/2 activation has been highlighted regarding the survival of cells after 
detachment. It has been reported that sustained MAPK/ERK1/2 activity was required 
for EGFR-dependent survival of keratinocytes in suspension culture [190]. In 
pancreatic cancer cells, enhanced ERK1/2 activity after cell detachment was 
essential for protecting cells from anoikis via regulating BCL-2 expression [191]. 
Moreover, since downregulation of activated ERK1/2 preceded activation of 
caspases 3 and 8, apoptosis may be induced by p-ERK1/2 downregulation causing 
blockage of cell entry into mitosis. 
In contrast with ERK1/2 downregulation, JNK expression was upregulated when 
U251-E cells were re-seeded at high density, as well as when they were incubated 
with conditioned medium from detached U251-E cells. It has been shown that JNK is 
inactive in U251 cells [192]. Given the important role of JNK in stress-induced 
apoptosis, it was hypothesized that elevated JNK was involved in apoptosis after re-
plating of cells at high density, which was further confirmed by the starvation 
experiment. After starvation, re-plating of U251-E cells at high density did not induce 
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apoptosis and JNK was not activated, further supporting the essential role of JNK in 
apoptosis. Next, the present results identified that JNK activation was probably, in 
part, mediated via IGF-1R pathway. However, the role of IGF-1R/JNK in induction of 
apoptosis remains controversial. Fan et al. indicated that activated JNK as a 
downstream growth signal of IGF-1R played a proliferative role in E2-induced 
apoptosis in breast cancer cells [193]. Besides, other mechanisms mediating JNK 
activation have been documented. Yang et al. reported that Sef, a feedback inhibitor 
of FGFR signaling, activated JNK and apoptosis via TGF-β associated kinase 
/MKK4/JNK pathway, proving a role of FGFR signaling in JNK activation [194]. 
Moreover, Yu et al. showed that α-PDGFR signaling played a role in anti-
transformation by activating JNK, critical for PDGF-regulation of apoptosis [195]. 
Other than RTKs, TNF receptor-associated factor 2 has been demonstrated to be 
involved in JNK mediated apoptosis through apoptosis signal-regulating kinase 1 
/MKK/JNK signaling pathway [196]. Thus, it is necessary to further investigate the 
mechanisms underlying JNK activation.  
It has been proposed that JNK and ERK1/2 play distinct roles in the context of 
apoptosis. Activation of JNK and inhibition of ERK1/2 were reported to be critical for 
induction of apoptosis, suggesting the balance between these two kinases is 
important in determining cell fate [197]. Based on the previous finding that IGF-1R 
was responsible for ERK1/2 activation which has a mitogenic effect, the current study 
showed that IGF-1R partially mediated JNK activation involving cell apoptosis. In 
total, the present results implied that the balance between mitogen-activated ERK1/2 
and stress-activated JNK pathways mediated via IGF-1R regulated proliferation and 
survival of U251 glioblastoma cells. 
4.2.2 Effect of ERK1/2 on radiation response 
The clonogenic survival results showed that radio-sensitivity of cells from U251-P did 
not significantly differ from that of cells from U251-E. To be noted, cells from U251-P 
had a significantly higher surviving fraction at 2Gy compared with cells from U251-E 
(0.76 ± 0.02 vs. 0.66 ± 0.03, P< 0.01), suggesting a more radio-resistant phenotype 
in cells from U251-P to some extent. The data of immunostaining with H2AX 
revealed higher capacity of DSBs repair in cells from U251-P when exposed to 2Gy. 
However, at high doses of 8Gy, no differences were found in two groups. One 
possibility may be the saturation of repair ability at high doses [198].  
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Cells from U251-P exhibited a relatively more radio-resistant phenotype, which may 
be the result from enrichment in G0/G1 phase of cell cycle and enhanced ERK1/2 
signaling upon release from substrate. Substantial evidence revealed that ERK1/2 
signaling plays an important role in regulating response to radio- and chemotherapy. 
Golding et al. addressed the requirement of EGFR/MEK/ERK1/2 signaling pathway 
for efficient DNA damage repair induced by irradiation, which contributed significantly 
to the increased radio-resistance in GBM [199]. In GBM cell line U87 and primary 
GBM cells, radio-sensitivity was promoted by a decrease of ERK1/2 activation 
following inhibition of hexokinase 2, while constitutive activation of ERK signaling 
rescued the increased DNA damage and enhanced radio-resistance [200]. Moreover, 
Marampon et al. reported that radiation treatment increased MEK/ERK1/2 pathway 
activation, which in turn contributed to radio-resistance in GBM cells [201]. In addition 
to radio-resistance, Sato et al. provided the evidence that ERK1/2 pathway mediated 
MGMT expression, leading to TMZ resistance via MDM2-p53 axis. Consequently, 
targeting ERK1/2 pathway by MEK inhibitor increased the sensitivity of stem-like 
glioblastoma cells to TMZ [202].  
Concerning translational aspect, cells remaining at the edge of the cavity after tumor 
debulking can be regarded as cells from plateau phase. The enhanced 
MAPK/ERK1/2 signaling may contribute to radio-resistance and thus early 
recurrence. Thus, targeting IGF-1R/ERK1/2 signaling has potential clinical 




Figure 29. Schematic illustrations of the balance of ERK1/2 and JNK pathways upon 
GBM cells detached from ECM. Plateau phase cells detached from ECM resulted in 
enhanced ERK1/2 signaling pathway which can be mediated via autocrine mechanism and 
other RTKs. The balance between ERK1/2 and JNK signaling pathway plays vital roles in 
anti-apoptosis, radio-resistance and proliferation in GBM cells, leading to tumor relapse. 
4.3 Role of cyclin-dependent kinase inhibitor p27 
Cyclin-dependent kinase inhibitor p27 controls cell cycle progression through G1 
phase. The absence of cell cycle checkpoint is a hallmark of tumor cells, which leads 
to uncontrolled proliferation [203]. Deregulation of p27 has been implicated in 
tumorigenesis and malignant progression in many cancers, and loss of p27 protein is 
frequently observed in various types of tumors [204, 205]. The current results implied 
the significant role of p27 as a cell cycle regulator in the regulation of GBM cells. The 
expression of p27 was elevated in U251-P cells but absent in U251-E cells. This 
contrasts with the findings by Fuse et al., in which U251 cells lacked the capacity of 
p27 induction [155]. However, another study assessed 12 established GBM cell lines 
including U251 cell line and found p27 expression was increased in all cell lines 
under the conditions of confluence or serum deprivation [206]. The expression of p27 
can be also influenced by other unfavorable changes in microenvironment. In an 
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immunohistochemical analysis of human GBM, high levels of p27 expression were 
maintained in hypoxic areas present within the tumor [207].  
Regarding the clinical value, it has been reported that low p27 expression was 
associated with poor prognosis and short survival in GBM patients [208], especially 
linked to cytoplasmic expression of p27 [209]. Therefore, restoring p27 expression 
has become a promising approach for GBM gene therapy. Komata et al. reported 
that overexpression of p27 by using recombinant adenoviral vectors suppressed cell 
growth in several GBM cell lines in vitro [210]. In vivo, Schiappacassi et al. showed 
that induction of p27 by adenoviral system inhibited GBM cell growth as well as local 
invasion and tumor induced neoangiogenesis [211]. When tumor suppressor gene 
p27 was upregulated, GBM cell proliferation was inhibited in vivo and in vitro [212].  
In addition to the tumor suppressive role, it has also been demonstrated that the 
absence of this cell cycle regulator has impacts on induction of apoptosis. In 
fibroblast, loss of p27 led to apoptosis and functional p27 expression was able to 
protect cells from apoptosis [213]. Therefore, in the current study, the cause of 
apoptosis might be associated with the absence of p27 in U251-E cells, causing 
uncontrolled cell cycle progression. Additionally, the necessity of functional p27 was 
also confirmed by the fact that induction of p27 by starvation of U251-E cells 
abolished apoptosis. A similar protective function of p27 was observed in other 
reports. Masuda et al. demonstrated that induction of p27 enabled small cell lung 
cancer cells to escape from apoptosis and supported cell survival under unfavorable 
culture conditions for cell growth [214]. In T98G GBM cells, downregulation of p27 
expression induced apoptosis when S-phase kinase associated protein 2 was 
synergistically inactivated under conditions of growth factors deprivation [215]. These 
data revealed that the functional p27 is essential for cell survival not only in normal 
cells but also in GBM cells. 
The presence of functional p27 in U251-P cells, and the large proportion of cells 
arrested in G1 with low-Ki67 expression in PH cells on day 3, suggested that GBM 
cells preserve a certain degree of contact inhibition. Therefore, the present data 
showed that cells in colonies or spheres had low Ki67 expressions while still kept 
their stem-like potential. This contact inhibition was reversible since cells re-
proliferated after re-plating, which is in line with a recent study by Compos et al. 
[216]. By using label retention techniques in glioblastoma stem cells, they found 
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labelled cells with Ki67-low expression reacquired the ability to proliferate and form 
new colonies after re-plating.  Moreover, quiescence of these labelled cells was 
mostly controlled by cell-cell contact inhibition. The underlying mechanisms of growth 
regulation may be mediated via several pathways. Notch signaling is reported to play 
a role in the control of contact inhibition in neuron [217]. Hippo-YAP signaling 
pathway as well as mTOR signaling pathway participated in regulation of reversible 
cell density arrest [218]. In addition, macrophage migration inhibitory factor was 
shown to mediate contact inhibition in GBM cells in vitro, providing a new insight into 
growth processes in GBM cells [219]. These findings supported that GBM cell 
proliferation is under proper regulation by functional cyclin-dependent kinase 
inhibitors. 
4.4 Role of exogenous growth factors 
The previous data by Wang et al. illustrated the important role of IGF-1R in the 
mitogeinc signaling of U251 cells [91]. Thus, the requirement of growth factors 
including IGF-1 as essential components in vitro culture medium was further 
investigated. The present results demonstrated that single exogenous growth factors 
can barely support the growth of U251 cells when they were cultivated in the 
presence of EGF or FGF-2 alone. IGF-1 showed dose-dependent stimulation of U251 
cell proliferation. Of note, the combination of IGF-1 and FGF-2 provided a growth 
advantage approaching that stimulated by FBS. These results further confirmed an 
essential role of IGF-1 in growth of GBM cells compared with EGF and FGF-2. In 
several in vitro studies, IGFs system plays important roles in the progression of GBM. 
Friend et al. pointed out that the addition of exogenous IGF-1 can stimulate the 
growth of several glioma cell lines including U251 cells which were not capable of 
endogenous IGF-I or IGF-II production [220]. Similarity, Schlenska-Lange et al. 
showed administration of IGF-1 but not IGF-2 enhanced proliferation and migration of 
other three glioma cell lines [221].  
As another important mitogen, increased FGF-2 has been found in glioma compared 
with normal brain [69]. Loilome et al. showed FGF-2 had a growth stimulatory effect 
in 8 out of 10 GBM and GBM stem-like cell lines in concentration-dependent manner 
[222]. However, 100 ng/ml of FGF-2 resulted in a growth inhibitory effect in some 
GBM cell lines [222]. Combining FGF-2 with IGF-1 supported growth of U251 cells. 
This can be explained by the fact that FGF-2 interacts with the IGF pathway by 
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increasing IGF-1R expression, thus enhancing activity of IGF-1 ligand [223]. 
Moreover, it has been found that FGF-2 coordinated with IGF-1 to enhance 
proliferation of primary oligodendrocyte progenitors by synergistically regulating cell 
cycle progression past G1/S transition [224]. In NCH644 glioma stem-like cells, FGF-
2 was slightly more effective than EGF and IGF-1. The critical role of FGF-2 has 
been implicated in GSC. It is well established that FGF-2, along with EGF, is a 
necessary supplement in culture medium of GSC in vitro [72]. Besides, of the two 
exogenous mitogens used in cell culture, FGF-2 had a stronger influence on growth 
of GSC than EGF [225, 226]. The insufficient effect of EGF on growth of GSC may 
result from loss of EGFR expression in the presence of EGF in vitro [226]. 
Furthermore, the addition of IGF-1 enhanced growth of NCH644 cells, indicating the 
stimulatory effect of IGF-1 on GSC. Arsenijevic et al. demonstrated that IGF-1 was 
essential for EGF/FGF-2 to promote proliferation of neural stem cells [81]. Aberg et 
al. showed that IGF-1 and FGF-2 were required for maximal proliferation and IGF-1 
had impacts on generation of new neurons in adult hippocampus [227]. Substantial 
evidence revealed that FGF-2 and IGF-1 have cooperative effects on regulation and 
proliferation of stem cells in vitro [228, 229]. Therefore, the importance of IGF-1 
should be taken into consideration when cultivating patient-derived glioblastoma cells 
in vitro. 
In conclusion, U251 cell proliferation was influenced by culture conditions including 
cell density as well as growth factors. The limited proliferation with cell apoptosis was 
seen when exponentially growing U251 cells were re-seeded at high density, which 
was associated with decreased p-ERK1/2, increased p-JNK and low p27 expression. 
The strong activation of ERK1/2 in plateau phase U251 cells upon release from 
substrate contributed to increased proliferation after re-seeding at high density, and a 
more radio-resistant phenotype to some extent. Moreover, a reversible contact 
inhibition was detected in GBM cells, suggesting cyclin-dependent kinase inhibitors 
remain some functionality. Besides, the addition of IGF-1 with FGF-2 and/or EGF 
provided a growth advantage in GBM cells in vitro, suggesting the important role of 
IGF-1R signaling pathway in GBM proliferation. The findings of the present work 
indicated the balance between mitogen activated ERK1/2 and stress activated JNK 
signaling pathways mediated via IGF-1R signaling, as well as functional cyclin-
dependent kinase inhibitors might play important roles in proliferation and survival of 




GBM cells are characterized by uncontrolled proliferation and resistance to 
apoptosis, which leads to undesirable clinical outcome, specifically poor prognosis in 
patients. A previous study by our group showed that passage of exponentially 
growing U251 cells (U251-E) and re-seeding at high density resulted in complete 
downregulation of ERK1/2 phosphorylation, whereas ERK1/2 activation was more 
strongly upregulated when U251 cells were harvested from plateau phase (U251-P). 
This suggested that releasing cells from density arrest provided a strong mitogenic 
signal which had an effect on GBM cell proliferation.  
In the present work, the impacts of the dysregulated ERK1/2 activity induced by 
changes in culture conditions including cell density were studied in U251 cells. A 
major result was that ERK1/2 activation suggested increased proliferation upon re-
plating of U251-P at high density, while ERK1/2 downregulation led to limited 
proliferation with cell apoptosis when re-plating of U251-E at high density (EH). The 
limited proliferation was associated with G2 accumulation (35%) and dysregulation of 
cell cycle proteins including p27, cyclin D1 and PLK-1. Upregulation of p27 in U251-E 
cells upon starvation enabled the cells to survive and continue to proliferate with no 
obvious detachment after re-seeding at high density, thus supporting a role for 
uncontrolled cell cycle progression in inducing apoptosis. Although FAK activation 
was suppressed, EH cells were not rescued from apoptosis by the induction of FAK 
expression. The results suggested that the downregulation of FAK signaling pathway 
was not responsible for the decreased ERK1/2 activation and that cell apoptosis in 
this case did not depend on FAK.  
To explore the underlying mechanisms of ERK1/2 downregulation in EH cells, 
ERK1/2 activation in parent cultures was further studied. The results showed a 
fundamental difference of ERK1/2 and JNK regulation in parent cultures. ERK1/2 
activation in U251-P cells was strongly upregulated upon loss of attachment. MEK 
inhibitor U0126 significantly inhibited ERK1/2 activation which was induced by 
conditioned medium from detached U251-P cells (P< 0.05), indicating a role of 
autocrine signaling. Furthermore, conditioned medium from detached U251-E cells 
increased JNK activation, which was significantly reduced by IGF-1R inhibitor 
AG1024 (P< 0.05). The results suggested the increased JNK activation, partially 
Summary 
78 
mediated via IGF-1R signaling in U251-E cells, contributed to apoptosis after re-
seeded at high density. To characterize the radiation sensitivity of U251 cells from 
different parent cultures, colony forming assay was performed. Although the 
clonogenic survival curves were very similar for immediate plating of cells from both 
phases, surviving fraction at 2Gy was significantly higher in cells from U251-P than 
from U251-E (0.76 ± 0.02 vs. 0.66 ± 0.03, P< 0.01). Immunostaining with H2AX 
showed a significantly higher foci number at 1h and 3h after 2Gy irradiation in cells 
from U251-P (1h: 27.81 ± 2.62 vs. 19.96 ± 0.58, P< 0.01; 3h: 22.52 ± 0.74 vs. 18.15 
± 1.16, P< 0.01, respectively). The results indicated that re-seeded U251-P cells 
exhibited a relatively more radio-resistant phenotype to some extent.  
In addition, a reversible contact inhibition was detected in U251 cells as well as 
NCH644 glioma stem-like cells. Ki67 positive cells were mainly at the periphery of 
spheres while cells in the inner part with low Ki67 expression showed density arrest 
by cell-cell contact, which was reversible by release from contact inhibition. Besides, 
the combination of IGF-1 and FGF-2 provided a growth advantage approaching that 
stimulated by FBS in U251 cells. In NCH644 cells, FGF-2 was slightly more effective 
than EGF and IGF-1 and the addition of IGF-1 with EGF and FGF-2 enhanced 
growth of NCH644 cells.  
Taken together, these results highlight certain molecular regulations preserved in 
GBM cells, specifically, (a) that a balance between mitogen activated ERK1/2 and 
stress activated JNK pathways mediated via IGF-1R pathway regulate GBM cell 
proliferation and survival, (b) that cyclin-dependent kinase inhibitors remain some 
functionality in GBM cells, which guarantees the proper cell cycle progression 
coordinated with mitogenic signaling, (c) and that these regulatory mechanisms 
contributed to cellular homeostasis and can provide a better understanding of the 
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